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Abstract 
 
Bile acid malabsorption or diarrhea (BAM or BAD) is a syndrome of chronic watery diarrhoea 
diagnosed predominantly by a SeHCAT test and less commonly by measuring levels of 7-
hydroxy-4-cholesten-3-one (C4) and furthermore responds to bile acid sequestrants (BAS). 
Primary bile acid diarrhoea (PBAD) is the condition with no definitive cause and is under 
diagnosed, often being labelled as IBS-diarrhoea with an associated burden of disease for 
patients. Recently an alternative mechanism for PBAD involving impaired Fibroblast Growth 
Factor (FGF19) production has been proposed. 
 
Aims:  The primary aims were to prospectively recruit patients with chronic diarrhea, and 
define them into groups of BAD, or chronic diarrhoea with normal SeHCAT; characterisation 
with SeHCAT, C4 and serum FGF19; investigation of genetic differences involved in bile acid 
metabolism.   
 
Methods: 152 patients recruited had routine investigations for chronic diarrhoea including 
SeHCAT test. Fasting serum FGF19, C4 and bile acids levels were measured from blood 
samples and relationships examined; FGF19 optimisation, response of BAS on PBAD patients 
and on FGF19 levels, effect of bowel preparation & short bowel syndrome (SBS) on FGF19 
levels were measured. 11 PBAD patients were studied through the day to examine variations 
in FGF19. 6 SNPs in genes involved in bile acid metabolism were analysed in PBAD patients. 
 
Results: Significantly lower fasting levels of FGF19 and increased levels of C4 were seen in 
patients with BAD with associations with Body Mass Index. Sensitivities and specificities for 
FGF19 against known tests were calculated. Excellent responses to BAS with no significant 
effect of bowel preparation on FGF19 and variable patterns during the day were seen.  
Reduced FGF19 levels were seen in SBS. SNPs studied in PBAD and control patients have yet 
to show any significant differences in frequencies. 
 
Conclusion: This research has confirmed that levels of an easily measurable and stable 
hormone, FGF19 are reduced in patients with BAD and is not affected by chronic diarrhoea 
per se. The work provides evidence of a disordered FGF19 production in PBAD patients, failing 
to reduce bile acid secretion and resulting in excess bile acids entering the colon causing BAD. 
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1. Introduction 
 
1.1 Bile acid synthesis and the enterohepatic circulation 
 
Bile acids (BAs) are synthesised in the liver from cholesterol and in conjugated form are 
transported into bile ducts. They then accumulate and are stored in the gallbladder where 
they flow into the duodenum following meal-stimulated gallbladder contraction. After 
delivery into the intestinal lumen, and their involvement in micelle formation in the small 
intestine, the vast majority are reabsorbed by the distal ileum into the portal circulation and 
returned to the liver.  Uptake of BAs by specific transport systems of hepatocytes takes place, 
and they are secreted again into bile. This process of recycling is called the enterohepatic 
circulation. A very small percentage of bile salts may be reabsorbed in the proximal small 
bowel by either passive or carrier mediated transport processes 1-3. Figure 1 depicts the 
enterohepatic circulation. 
 
 
 
Figure 1: Enterohepatic circulation of bile acids. 
 
During fasting, bile acids are sequestered and concentrated approximately 10-fold in the 
gallbladder, resulting in low levels of bile acids in the small intestine, portal vein, serum and 
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liver.  Overall the enterohepatic cycling of bile acids increases during digestion and slows 
between meals and during overnight fasting 4. 
 
 
1.2 Function and characteristics of bile acids 
 
Bile formation plays a vital role in intestinal lipid digestion and absorption, cholesterol 
homeostasis and excretion of lipid soluble xenobiotics (substances naturally present in or 
added to foods that do not contribute usefully to metabolic function) and heavy metals. BAs 
form mixed micelles with fatty acids and monoglycerides, which in turn solubilise fat soluble 
vitamins. Micelle formation accelerates dietary lipid absorption 5. Bile acids also function to 
denature dietary proteins allowing accelerated cleavage by pancreatic proteases 3. The 
maintenance of hepatic bile formation is essential for normal liver function. Disturbance in BA 
homeostasis can lead to liver disease, cholesterol gallstones and malabsorption. A number of 
feedback mechanisms exist in order to sustain sufficient pools of BAs 6. 
 
A small proportion of BAs secreted escapes the intestinal absorption (3-5%) and is irreversibly 
excreted in the faeces 7. About 95% of BAs are recycled due to reabsorption in distal ileum by 
an efficient and well characterised sodium dependent apically located bile acid transporter 
system 8, 9.  
 
Studies by Ung et al in 2004 to determine active BA absorption in small biopsy specimens, 
obtained endoscopically or surgically from human intestine, showed that active uptake of BAs 
occur in the very distal part of ileum and up to 100cm proximal to ileo-caecal valve 10.  
 
In the course of history, Alan Hoffman has been a leading scientist in the discovery of the 
roles of BAs and their physiology 3. Estimates of the average kinetics of bile acids are shown in 
Table I.   
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BA secretion 12 g/d  or equivalent  30 mmol/d 
BA pool size 2 – 3 g or equivalent  5 - 7.5 mmol 
Cycling frequency   4 – 6 x/d  
Amount absorbed / cycle ~ 95%  
Faecal BA loss <  0.5 g/d or equivalent  ~ 1 mmol/d 
Average half-life ~ 3 d  
 
Table 1:  Bile Acid Kinetics in a typical adult 11. 
 
A small proportion of the secreted bile acids are not reabsorbed in the ileum and reach the 
colon.  Here bacterial action results in deconjugation (removal of the taurine or glycine) and 
dehydroxylation (removal of the 7-hydroxy group), producing the secondary bile acids, 
deoxycholate and lithocholate. 
 
 
1.3 Bile Acid synthesis 
 
Bile acid synthesis occurs via two pathways: the classical pathway (neutral pathway), which 
utilises microsomal cholesterol 7α-hydroxylase (CYP7A1), or by mitochondrial sterol 27-
hydroxylase (CYP27A1) of the alternative (acidic pathway) 12. The classical pathway begins 
with 7α-hydroxylation of cholesterol catalysed by CYP7A1, which is thought to be the rate 
limiting step in BA synthesis 7 (Figure 2).  
 
The classical pathway of BA synthesis occurs exclusively in the liver and gives rise to the two 
primary BAs: cholic acid and chenodeoxycholic acid. The types of the common mammalian BA 
and their individual kinetics are shown in Table 2. 
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Common Name Type  Pool size (mg) Daily synthesis 
(mg) 
Cholic acid Primary 
 
Synthesized 
from cholesterol 
by liver 
500-1500 180-360 
Chenodeoxycholic acid Primary 
 
500-1400 100-250 
Deoxycholic acid Secondary 
 
Produced in 
intestine from 
action of 
microorganisms 
on primary bile 
acids 
200-1000  
Lithocholic acid Secondary 
 
50-100 
 
 
 
                 Total 1250-4000 280-610 
 
Table 2:  Names and kinetics of individual bile acids in humans 4. 
 
 
Figure 2: Pathway for production of bile acids from cholesterol. 
 
In humans, the classical pathway is thought to be quantatively more important of the two 
major BA synthesis pathways.  The evidence supporting this comes from the finding that bile 
acid production was significantly reduced in an adult patient with an inherited CYP7A1 defect 
in the neutral pathway 13. In contrast with adults, however, the acidic pathway may be 
dominant in human neonates as is evident by the apparent lack of CYP7A1 in newborns and 
the finding of severe cholestatic liver disease in an infant with an inherited CYPYB1 defect 14, 
15.  
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One of the intermediate products in the bile acid synthesis pathway is 7α-hydoxy-4-
cholesten-3-one (C4). This is readily measurable in peripheral blood samples and its serum 
concentrations have been shown to accurately reflect the activity of hepatic cholesterol 7α 
hydroxylase (CYP7A1), the first enzyme and the rate-limiting step in bile acid synthesis 
pathway 16. 
 
The newly synthesised primary bile acids are conjugated with glycine or taurine and are 
readily secreted from the biliary tree into the duodenum following food ingestion. In humans 
the majority of biliary bile acids are conjugated to glycine 4.  Conjugation with taurine or 
glycine increases the hydrophilicity of bile acid and the acidic strength of its side chain. 
Consequently this decreases the passive diffusion of BAs across cell membranes during their 
transit through the biliary tree and small intestine 17. Conjugation of BAs are therefore only 
absorbed if a specific membrane carrier is present. The net effect of conjugation is to 
maintain high luminal micellar concentrations of BAs in order to facilitate lipid digestion and 
absorption down the length of small intestine. 
 
1.4 Bile acid transport in liver and intestine 
 
1.4.1 Transport in the liver 
 
Approximately 97% of bile acids secreted into bile originate from the recirculating pool. This 
efficient vectorial transhepatocellular movement of bile acids from the portal blood into bile 
is a concentrative transport process that involves a number of distinct primary (ATP-
dependent) and secondary (sodium (Na+) gradient-dependent) active transport systems at the 
sinusoidal and canalicular plasma membranes; Figure 3. 
 
The majority of the bile flow is via periportal hepatocytes (the first hepatocytes of the liver 
acinus) which primarily absorb and secrete recirculating bile acids whereas perivenous cells 
secrete predominantly new bile acids 2.  
 
The sinusoidal membrane based Na+ taurocholate co-transporting polypeptide NTCP (gene 
symbol SLC10A1) mediates the uptake of conjugated bile acids from the portal circulation into 
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the hepatocytes. The sinusoidal NTCP shares similar sequence identity and functional 
properties to the Na+ dependent bile acid transporter present in the ileal enterocyte.  
 
Although polymorphisms have been identified in the human NTCP gene, there is no 
phenotypical correlation with regards to how this may affect bile transport; inherited NTCP 
defects in patients have not been identified and a NTCP knockout mouse model has yet been 
generated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Bile acid transport in the liver. BAs activate FXR, inducing SHP expression, which 
further inhibits LRH-1 & transactivation of CYP7A1. Returning FGF19 from ileum activates 
FGFR4 which in turn also inhibits CYP7A1 via the SHP-LRH pathway.  
 
Newly synthesised and recirculating BAs are subsequently actively secreted from hepatocytes 
into the bile canalicular lumen by the action of Bile Salt Export Pump (BSEP; gene ACBCB11). It 
is highly expressed in hepatocytes and efficiently pumps conjugated bile acids.  The role of 
BSEP as the major canalicular bile acid efflux pump was confirmed by the identification of 
mutations in the BSEP gene causing dysfunction of the gene products in patients with 
progressive familial intrahepatic cholestasis type 2 18 . 
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1.4.2 Transport in the intestine 
 
Conjugated bile acids are absorbed from the intestine by a number of mechanisms. Some 
passive absorption occurs throughout the small intestine through paracellular junctions that 
are sufficiently large enough to permit passage of conjugated bile acid anion 19. 
 
The majority of bile acid absorption, however, occurs in the terminal ileum, and this has been 
evident through a number of studies; this has included intestinal perfusion studies in humans 
showing greater ileal absorption than jejunal absorption, and profound bile acid 
malabsorption in patients following ileal resection 20.  
 
The transport molecules involved in the uptake of conjugated bile acids in the ileum (Figure 4) 
starts with the apical sodium-linked bile salt transporter (ASBT) at the brush-border 
membrane and is encoded by the gene SLC10A2 21. This is an active transport system that 
specifically allows uptake of only conjugated and unconjugated bile acids with very limited 
uptake of other organic anions, and its expression is limited to the terminal ileum. Studies 
have shown that ASBT is crucial to the cycle of uptake of BAs with breakdown of the EC with 
targeted deletion of the ASBT gene in mice 22.  
 
Transport through the cytoplasm is via the ileal bile acid binding protein (IBABP, gene 
FABP6)23.  IBABP may not be essential for ileal BA transport as mouse models lacking IBABP 
expression showed no impairment in intestinal bile acid absorption, and therefore may 
function to bind bile acids during higher intracellular concentrations and protect the ileal 
enterocyte integrity from bile acid toxicity 24.  
 
Extrusion occurs at the basolateral membrane and is now thought to occur through the organic 
solute transporter heterodimer α and β subunits (OSTα & β) 3, 11. These transporters are up-
regulated on exposure to higher concentrations of BAs, with studies showing their expression 
generally following that of ASBT with the highest concentration found in the terminal ileum; in 
addition they are also found at other sites of bile acid efflux including hepatocytes 25, 26. Figure 
4 follows the BA journey in the ileum. 
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Figure 4:  Bile acid transport in the ileum 27. BAs (yellow circles) taken up by enterocytes in 
the ileum via ASBT, and travel through the cell attached to IBABP, and are finally extruded 
by OSTα/OSTβ.  
 
 
1.5 Regulation of bile acid synthesis and their diurnal variation 
 
The regulation of bile acids is by a homeostatic mechanism in which bile acids returning to the 
liver from the distal ileum via the portal circulation inhibit their own synthesis (negative 
feedback); this concept is mainly applied to the classical pathway with a negative BA feedback 
loop acting on CYP7A1.  
 
Central to the control of BA synthesis is the Farnesoid X Receptor (FXR). FXR is a member of 
the steroid/thyroid hormone receptor family of ligand-activated transcription factors. This 
orphan nuclear receptor is activated by bile acids and activates expression of genes involved in 
BA metabolism 28. Genes controlled by FXR include those encoding short heterodimer partner 
(SHP), IBABP, OSTα & β, ASBT and FGF15/19. BAs vary in their potency as FXR agonists, with 
Na+
SLC10A2:
Also known as
Apical sodium-dependent bile acid 
transporter (ASBT)
Ileal bile acid transporter (IBAT) 
FABP6:
Also known as
Ileal lipid-binding protein (ILBP)
Ileal bile acid-binding protein 
(IBABP) 
OST- /OST- heterodimer
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studies showing that some such as chenodeoxycholic acid act as powerful ligands while other 
BAs such as cholic acid are less potent 7. 
 
In the classical regulatory pathway the returning BAs bind to a nuclear FXR in the liver, which 
induces expression of Small Heterodimer Partner (SHP), which in turn inhibits the expression 
of Liver Receptor Homologue 1(LRH1); this is an orphan receptor required for CYP7A1 
promoter activity and also required for expression of sterol 12α-hydroxylase (a cytochrome 
P450 required for production of cholic acid); overall transcription of CYP7A1 is suppressed 29.  
 
Studies have revealed that removal of elements of the FXR-SHP pathway did not abolish the 
ability of BAs to self regulate themselves, and therefore a further second pathway in addition 
to hepatic cascade of events and independent to activation of SHP transcription must be 
present.  
 
This concept of feedback regulation of bile acid synthesis in the liver comes from studies 
elucidating to an intestinal secreting factor that would suppress hepatic cyp7a1 activity; bile 
duct ligation in rodents resulted in a hepatic overload in BAs but also unexpectedly showed an 
increase in CYP7A1 activity suggesting that bile duct ligation removed the activity of a 
signalling agent from the intestine 30, 31. 
 
Recent studies in mice indicate that intestinal Fibroblast Growth Factor 15 (FGF15) may 
function as a secretory signal acting on the liver through the hepatic FGF receptor 4 (FGFR4) 
and leading to suppression of CYP7A1 through the c-Jun NH2-terminal kinase (JNK) pathway 
32, 33. The expression of FGF15 mRNA was inversely correlated to CYP7A1 mRNA expression 
levels in the mouse liver. Restoration of FGF15 in the intestine, via GW4064 treatment (an 
FXR agonist) enabled repression of CYP7A1 activity in the bile duct ligated animal 32. 
 
Additional support for FGF19 signalling role comes from studies showing elevated CYP7A1 
expression, cholesterol 7a-hydroxylase protein levels, and faecal bile excretion seen in FGF15 
-/- mice. Furthermore, suppression of CYP7A1 was not seen in GW4064 treated FGF15 -/- 
mice suggesting FGF15 is required for FXR mediated bile acid feedback suppression of 
CYP7A1. 32  
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 Again crucial to this regulation of bile acid synthesis is FXR, which in the ileocyte expresses 
FGF19 in response to BAs. GW4064 was shown to repress CYP7A1 in the liver- specific FXR 
knockout mice but not in intestine-specific FXR knockout mice confirming that intestinal FXR 
is required for bile acid inhibition of CYP7A1 gene expression and indicating the 
predominance of the FGF19 regulatory mechanism 34.  
 
β Klotho, a membrane bound glycosidase protein co-expressed with FGFR4 in hepatocytes 
modulates FGFR4 function and allows FGF19 activation of FGFR4 signaling. It is thought that 
the activity of FGFR4 depends upon its form of glycosylation, and it is through modulating this 
glycosylation that β Klotho exerts its effect 35. 
 
Studies have previously shown that mice lacking FGFR4 exhibited elevated fecal BAs, bile acid 
pool size, and expression of CYP7A1; conversely over expression of a constitutively active 
human FGFR4 repressed CYP7A1 activity by 70-90% and decreased bile acid pool by 
approximately 50% when compared to wild type mice 36, 33. These results support the critical 
role of FGFR4 signaling in regulating bile acid synthesis through a feedback mechanism. 
 
This complex molecular cascade allows bile acid synthesis to be both linked to both intestinal 
and hepatic bile acid levels. Figure 5 summarises the regulation of BAs through CYP7A1.  
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Figure 5: Model of BA regulation. Transhepatic and transintestinal BA flux results in the 
activation of FGF15/19 in the small intestine and SHP in the liver. These pathways 
cooperate to repress CYP7A1 in the liver, thus reducing BA synthesis 32. 
 
 
FGF15 and its human orthologue FGF19 has been shown to be expressed in the small 
intestine and more recently it has been shown that BAs within the liver itself may activate the 
liver FGF19/FGFR4 signalling pathway to inhibit bile acid synthesis and prevent accumulation 
of toxic bile acid in the liver 37. This may well be a protective adaptation, particularly under 
conditions of extrahepatic cholestasis 38. 
 
Recently work by Schmidt et al on mice have shown a unexpected regulatory mechanism of 
bile acid synthesis by fat-soluble vitamins A and D by repressing hepatic expression of CYP7A1 
through inducing expression of FGF15. Induction of FGF15 by vitamin D occurs via its 
receptor, whereas induction by vitamin A occurs through FXR and its heterodimer, Retinoid X 
Receptor (RXR) 39.  
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1.5.1 Diurnal variation 
 
Further support with regards to FGF19 playing an important hormonal role in the regulation 
of bile acid synthesis is the diurnal variation that mimics BA levels during the day.  
 
BA synthesis in humans has a diurnal variation with two distinct peaks during the day: the first 
at 1pm and the second at 9pm; this has been shown by measuring levels of 7-hydroxy-4-
cholesten-3-one (C4) which strongly relate to the hepatic enzymatic activity of CYP7A1 and 
therefore bile acid synthesis 40.  
 
Work done by Lundasen showed that FGF19 has a diurnal rhythm with 2 peaks occurring 
around 3 and 9pm; FGF19 peaks in serum with a delay of 90-180 minutes following the peak of 
serum BAs 6. This pattern is shown in Figure 6.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Diurnal changes of total 
BAs, FGF19, and BA synthesis in 
healthy volunteers 6.  
 
 
 
It was also found that FGF19 levels reduced when patients were given a BA sequestrant and 
rose following feeding with chenodeoxycholic acid. C4 levels, however, were suppressed 
approximately 2 hours after serum FGF19 levels peaked. Under fasting conditions, serum bile 
acids and serum FGF19 remained low, and bile acid biosynthesis in the liver increased by 100%. 
This pattern further provides evidence to the model of postprandial bile acid induction of 
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intestinal FGF19 (via FXR) which then signals to the liver, repressing CYP7A1 and overall bile 
acid synthesis. It is likely that FXR-FGF19-FGFR4 pathway is the physiological homeostatic 
mechanism for bile acid feedback regulation of bile acid synthesis. 
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1.6 Fibroblast Growth Factor 19  
 
FGF 19 belongs to a family of FGF’s, found in many species including humans, and consists of 
at least 22 highly conserved proteins 41. FGFs have a core 120 amino acid FGF domain which 
confers a common tertiary structure. FGFs are expressed during embryonic development and 
in certain adult tissues. The FGF19 subfamily has reduced heparin binding which allows them 
to diffuse beyond their site of origin and act as classical endocrine hormones, i.e. secreted in 
one tissue and bind and signal in a distant target tissue 42. 
 
Human FGF19 cDNA predicts a 251 amino acid  precursor protein with a 22 amino acid signal 
peptide and a 229 amino acid  secreted mature protein with no potential N-linked 
glycosylation sites 43. Human FGF19 shares 53% amino acid sequence identity with mouse and 
rat FGF15 and 62% amino acid  sequence identity with chicken FGF19 43, 44.  
 
FGF19 expression is regulated by Farnesoid X receptor, which as mentioned is a nuclear 
hormone receptor that is a key regulator of bile acid biosynthesis and transport.  
 
FGFs bind and signal through fibroblast growth factor receptors (FGFRs), which are plasma 
membrane tyrosine receptor kinases; there are four receptors, FGFR 1-4. Unlike most FGFs, 
which bind to and activate more than one FGF receptor, FGF19 appears to bind and activate 
only FGFR4 45. FGFs also bind to heparin sulphate proteoglycans which act to increase the 
affinity and stability of the FGF-FGFR complexes. 
 
FGF19 along with -21 and -23 have several properties in common that are atypical for the FGF 
family; they are transcriptionally regulated by a nuclear receptor class of ligand activated 
transcription factors. FGF19 expression is regulated by FXR, while FGF21 expression, for 
example is regulated partially by the vitamin D receptor. 
 
FGF19 hormone relies on β Klotho proteins, single pass transmembrane proteins, which 
stabilises the FGF-FGFR interaction to allow activation of downstream signalling 46. The 
presence of β Klotho, selectively permits FGF19 binding and signalling through FGFR4. FGF19 
interaction with β Klotho is seen in the liver and to a lesser extent in adipose and pancreas.  
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1.6.1 FGF19 Function 
 
The functional roles of FGF19 include developmental, metabolic and tumorigenic activities. 
In addition to the regulation of bile homeostasis and enterohepatic signalling with a diurnal 
variation as discussed earlier, FGF19 also has a number of other functions and effects.  
 
Cholecystokinin (CCK) is released from the proximal duodenum in response to feeding and 
stimulates gallbladder emptying. Conversely, intestinal FGF15 and FGF19 have been identified 
as regulators of gallbladder filling. Evidence for this is derived from studies showing that 
FGF15 -/- and FGFR4 -/- mice have small depleted gallbladders 47. Administration of 
recombinant mouse FGF15 or human FGF19 to FGF15 -/- mice resulted in a vastly increased 
and prompt gallbladder volume, probably via signalling through the endocrine action of 
intestinal FGF15 and FGF19, as FGF19 is not expressed in the gallbladder, common bile duct 
or the Sphincter of Oddi.  
 
Metabolic effects of FGF19 have been studied in animal studies showing the FGF19 transgenic 
mice have a higher metabolic rate, independent to other hormones controlling obesity. FGF19 
mice maintained a lean phenotype with decreased muscle and liver triglyceride levels during a 
high fat diet for 12 weeks. These mice also had lower serum glucose and insulin levels, 
improved glucose intolerance, and improved insulin sensitivity compared with wild type mice 
48. Similar studies in mice treated with recombinant FGF19 showed weight reduction and 
improvements in glucose metabolism and overall suggest that FGF19 acts as an insulin 
sensitizer independent of other hormonal signalling 49.  
 
Studies measuring serum FGF19 in obese patients awaiting gastric bypass surgery compared 
to a non obese cohort showed significantly lower median FGF19 levels in the obese 
individuals (122 vs 231 ng/l) with an increase in FGF19 levels and serum bile acids following 
gastric bypass surgery, and suggest an hormonal role of FGF19 in regulating metabolic 
changes in obesity 50, 51. 
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The liver has been shown to express elevated levels of FGF19 in patients with extrahepatic 
cholestasis and FGF19 signalling involvement may be an adaptive measure to protect the liver 
against liver toxicity 38. 
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1.7 Bile Acid Malabsorption/Diarrhoea 
 
Failure of absorption of bile acids by the distal ileum results in spillover of BAs into the colon 
where they cause typical symptoms of loose, watery stools; this condition is commonly 
known as Bile Acid Malabsorption (BAM).  The concept that bile acids can cause diarrhoea 
dates back to 1967 when it was first described by Alan Hofmann and was referred to as 
cholegenic diarrhoea or choleheic enteropathy 52.  
 
BAM, as discussed later, is not a ‘malabsorptive’ process, and has recently been correctly 
termed, Bile Acid Diarrhoea (BAD) 53; this condition will be referred to as BAD for the rest of 
thesis.   
 
BAs in the colon, particularly the dihydroxy BAs, chenodeoxycholic and deoxycholic acids, lead 
to this type of diarrhoea by various mechanisms including: 
 
1) inducing secretion of sodium and water, particularly at concentrations above  
3 mmol/l54 
2) increasing colonic motility 
3) stimulating defecation 
4) induce mucus secretion 
5) damage to mucosa increasing mucosal permeability 55. 
 
BAD has been divided into three types depending on their aetiology, as shown in Table 3 56. 
Primary, or idiopathic BAD occurs in the absence of ileal or other diseases and was first 
described by Hess Thaysen and Pederson 57, 58 and referred to as Type 2 BAD 59. 
 
 
1.7.1 Clinical aspects of bile acid diarrhoea 
 
Patients with mild to moderate bile acid malabsorption present solely with watery diarrhoea, 
while those with severe BAD may also have steatorrhoea. Other gastrointestinal symptoms 
reported in the literature include bloating, urgency, and faecal incontinence, which are 
probably related to an increase in motility and shortening of the colonic transit time 60. In 
34 
general, patients respond well to treatment with bile acid sequestrants, such as 
colestyramine, with significant reduction in bowel frequency and a better quality of life 61. 
 
Classification of BAD Aetiologies  
 
 
Type 1 
  Ileal Dysfunction 
  (Secondary BAD) 
 
 
Ileal Crohn’s disease, Ileal Resection,  
 
Results in failure to reabsorb BAs at the distal 
ileum leading to BA spillover into colon 
 
Type 2 
  Idiopathic Bile Acid       
  Malabsorption / diarrhoea (IBAM/D) 
  Primary Bile Acid Diarrhoea (PBAD) 
 
Unknown cause 
 
Mechanisms unclear. Discussed below  
 
Type 3 
Other Conditions 
 
 
 
 
Post-cholecystectomy, Post-vagotomy, 
Coeliac disease, Bacterial overgrowth, 
Pancreatic insufficiency (chronic pancreatitis 
& cystic fibrosis), Radiation ileitis 62, 
Microscopic/collagenous/lymphocytic colitis 
(associated in 40% of people with BAD 63, 64 
 
May involve alterations in small intestinal 
motility, BA cycling frequency, or composition 
of ileal contents 
 
Table 3: Classification and aetiology of BAD (Type 1-3).  
 
Idiopathic or Primary BAD, where there is no obvious cause, occurs in both men and women, 
mostly between the ages of 30 and 70 57. There is often a long history of diarrhoea, 
sometimes exceeding 10 years. The diarrhoea is continuous or intermittent, and nocturnal 
diarrhoea can occur. Mean stool volumes are moderately increased (240-290 g/day), but can 
be voluminous, up to 900 g/day 65. 
 
Although the condition is far from life threatening, it can have a significant impact on a 
patient's lifestyle due to the fact that the increased frequency of bowel motions often 
dictates the day-to-day functioning, limiting the ability to travel or leave the house (see 
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appendix 1 for patient quotes collected during patient recruitment relating to the effect on 
quality of life). 
 
BAD has been identified in frequent reports as a possible explanation for persistent chronic 
diarrhoea but it has commonly been regarded as rare and of limited importance in clinical 
practice and often a diagnosis that many gastroenterologists fail to consider 66. It is often far 
down the list of causes of chronic diarrhoea, and only considered after conditions such as 
inflammatory bowel disease, colonic cancer, coeliac disease and colonic infections have been 
excluded. 
 
Investigations to diagnose BAD such as a Selenium-homocholic acid taurine (SeHCAT) test60 
performed in nuclear medicine (see later) are not routinely performed at many district 
general hospitals; the diagnosis is then usually made by a trial of treatment. Overall this 
delays diagnosis and treatment and BAD is felt by experts to be an under-recognised cause of 
chronic diarrhoea. It is often misdiagnosed as diarrhoea-predominant irritable bowel 
syndrome (IBS-D). IBS patients are the largest group of patients seen in a general 
gastroenterology clinic.  
 
 
1.7.2 Prevalence of bile acid diarrhoea 
 
The prevalence of sub groups of BAD can vary; in one study Type 3 BAD represented 51% of 
all cases of patients positive for SeHCAT over a five year period. Post cholecystectomy was the 
commonest cause in this group and represented 24% of cases. Type 1 BAD was seen in 16% of 
cases of the positive SeHCAT group67. 
 
Many studies suggest that 30-50% of patients with previous unexplained chronic diarrhoea 
have BAD 56, 68. This could add up to substantial numbers of undiagnosed patients: with a 
population of 900 million people in the Western world, approximately 90 million people 
suffer from IBS, of whom 30 million will have IBS-D.  With the above estimates that 30-50% of 
IBS-D can be diagnosed with idiopathic BAD, this would result in at least 10 million people 
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with this condition in the West 69, or a population prevalence in the UK of approximately 1% 
70. 
 
Table 4 summarises a systematic review of studies which have estimated the prevalence of 
Primary BAD using SeHCAT scanning in patients with chronic diarrhoea, who were usually 
labelled as having diarrhoea predominant irritable bowel syndrome (IBS-D) 70. 
 
Reported SeHCAT value < 5% < 10% < 15% Total 
Number of studies reporting 5 17 7 18 
Total number of patients 429 1073 618 1223 
Number abnormal 43 339 163  
% abnormal  
(95% confidence intervals) 
10% 
(7 – 13) 
32% 
(29 – 35) 
26% 
(23 – 30) 
 
% response to colestyramine 96% 80% 70%  
 
Table 4: Summary of studies reporting abnormal SeHCAT values in patients with diarrhoea-
predominant IBS 53. 
 
 
1.7.3 Diagnosis of BAD 
 
1.7.3.1 SeHCAT test  
 
The commonly used test for diagnosis of BAD is the SeHCAT (Selenium-homocholic acid 
taurine) test. SeHCAT is a synthetic analogue of the naturally occurring bile acid taurocholic 
acid with the  emitting 75Se in the side chain 71,72. SeHCAT is resistant to deconjugation by 
intestinal bacteria and behaves like taurocholic acid with regards to enterohepatic cycling, 
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hepatic handling, active absorption from the terminal ileum, faecal excretion, and overall 
turnover in the enterohepatic circulation 73.  
 
The Se-labelled bile acid is administered orally and the total body retention is measured with 
a gamma camera after 7 days. Retention value of less than 10% is considered abnormal and 
indicative of BAD, although other studies have used a level of 15% or less as a positive test for 
BAD 74, 75. Diarrhoea in patients with greatly reduced SeHCAT retention usually responds to 
oral colestyramine which binds to bile acids in the gut 68. The SeHCAT test is able to evaluate 
BAD with a sensitivity of 80-90% and specificity of 70-100%. Figure 8 (page 45) shows the 
SeHCAT retention and cumulative faecal bile acid losses over 7 days with typical normal 
values of BA pool and cycling frequency (Figure 8a) and the effects of reducing bile acid 
absorption on each cycle from only 95% to 90%, resulting in a SeHCAT retention of less than 
10% (Figure 8b). SeHCAT offers a relatively low radiation dose to the patient (0.26mSv), 
equivalent to a plain chest x-ray, compared to a typical CT abdomen (3.0 mSv)76. 
 
However, the use of a radioactive test substance and the need for repeated measurements of 
radioactivity by a highly sensitive counting system restricts the general use of the SeHCAT 
test. Moreover, the SeHCAT test has not been approved by the drug administration agencies 
of many countries, including the USA, limiting awareness of this condition and its prevalence. 
 
Caution should be used in patients with liver disease as this condition may interfere with the 
SeHCAT results. In addition the presence of bacterial overgrowth in the small bowel may 
influence the interpretation of the SeHCAT test.   
 
 
1.7.3.2 Faecal Bile Acids 
  
Prior to the established use of SeHCAT in the 1980s, the diagnosis was based upon 
quantification of faecal bile acids in a 24-hour stool collection, where levels exceeding 
1.2mmol/l are considered abnormal 65. Some have argued that this is a more accurate 
measurement of bile acid loss and hence should be the ideal test to perform. The 
measurements of faecal bile acids, however, are not available in most hospital laboratories 
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and are now only performed in specialised research laboratories. Moreover the practical 
aspect of collecting 24 hour faecal collection is poorly reproducible and unpleasant for both 
the patient and laboratory technician. 
 
1.7.3.3 Trial of Treatment 
  
The general approach to the diagnosis of BAD as a cause of chronic diarrhoea in district 
general hospitals is a trial of a bile acid binder. If the treatment results in amelioration of 
diarrhoea, the response is seen as an indirect proof of BAD. BAD is a chronic condition and it 
is therefore important to establish the diagnosis as it requires lifelong treatment; furthermore 
due to the side effects of the original bile acid binders, compliance is an issue, and 
establishing the diagnosis is essential to titrate the drugs to response. 
 
1.7.3.4 Cholestenone 
 
Increased activity of hepatic cholesterol 7 hydroxylase (CYP7A1) results in increased BA 
synthesis, with a parallel increase in serum levels of the precursor, 7-hydroxy-4-cholesten-3-
one (C4). In patients with Primary BAD, BA synthesis has been shown to remain high, which is 
reflected by elevated levels of C4 77, 78. Levels of BA synthesis therefore can be determined by 
measuring C4 using a high pressure liquid chromatography (HPLC) test.  
 
The relationship between C4 and SeHCAT has been established in several studies. Eusufzai et 
al., in a study of 28 patients with chronic diarrhoea, were the first to show a significant 
positive correlation between the two tests 79. Brydon et al. evaluated SeHCAT and serum C4 in 
164 patients with chronic diarrhoea; they found a positive predictive value of serum C4 of 
74%, but a high negative predictive value of 98% for a SeHCAT retention value of <10%, 
suggested that this test could be used excluding BAD 77. Sauter et al determined a reference 
range of C4 in 106 normal subjects between 6 and 48ng/ml. In this study, 23 patients had 
chronic diarrhoea, and they found a sensitivity of 90% and a specificity of 79% for a SeHCAT 
retention of <10%, with a positive predictive value of 73% and a negative predictive value of 
92% 80. Figure 7 shows this significant negative correlation between the SeHCAT retention and 
C4.  
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Figure 7: Relationship of SeHCAT values at day 7 (%) and plasma concentrations of C4 in 
diarrhoea patients 78. 
 
 
 
The advantages of this test are that only a serum sample from the patient is needed, there is 
no exposure to radiation, and it is less time consuming for the patient. Measurement of C4 
however, is currently only performed routinely in one UK centre, and utilises an HPLC method 
which is a laborious process. Other methods have been developed for use elsewhere 81,82. 
Camilleri et al. used a liquid chromatography tandem mass spectrometry assay for C4, finding 
an interquartile range of 9.5 to 29.2ng/ml in 111 healthy volunteers, and elevated median 
levels in patients with ileal resection or disease, which in this study were greater than that 
found in patients with IBS-D 83. This method allowed a faster analysis for C4 (14 minutes per 
sample) and may potentially increase the availability of C4 assays.  
 
Other disadvantages of C4 measurements are that concomitant medication therapy including 
statin treatment may potentially affect bile acid synthesis rates 84. Also Cafistol has been 
shown to increase plasma levels of C4 in humans 85. 
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1.7.4 Treatment of BAD 
 
Treatment of bile acid diarrhoea is oral administration of bile acid binders. These adhere to 
the excess free bile acids in the small bowel and prevent the secretory action of bile acids on 
the colonic mucosa. BAD in patients with active inflammation of the terminal ileum in Crohn’s 
disease may improve with glucocorticoids to induce remission 86. The underlying cause should 
be sought after and treated for patients with Type 3 BAD, but they may also require a bile 
acid binder. 
 
There are currently three bile acid sequestrants available: colestyramine, colestipol, 
colesevelam. They have been shown to be effective in the control of bile acid-induced 
diarrhoea.  The standard dose for each sequestrant can be titrated up or down in the 
individual patient depending upon response. In my clinical experience one sachet of 
colestyramine taken at night is often sufficient in controlling diarrhoea. Addition of further 
doses can often lead to overcompensation resulting in constipation. These drugs are not 
absorbed in the intestine and therefore have no systemic side effects. The added benefit of 
the use of these drugs is their cholesterol lowering effect.  
 
Colestyramine and colestipol are anion exchange resins that form complexes with organic 
anions such as bile acids with high affinity 61. The main disadvantage of colestyramine is an 
unpleasant taste, which can lead to intolerability and poor compliance. Colestyramine has 
variable tolerance due to other side effects including nausea, borborygmi, flatulence, 
bloating, abdominal pain and constipation. They can be present in 30% of patients treated 
with colestyramine although the extent of severity is difficult to ascertain 67.   Both these 
medications have multiple drug interactions because of their unspecific affinity for organic 
anions. Simultaneous use may reduce absorption and serum concentrations of important 
drugs, such as digoxin, thiazide diuretics, beta blockers, thyroid hormones. It is recommended 
therefore that these drugs be administered two hours before the bile acid binders 87.  Vitamin 
absorption may also be impaired. 
 
Pooled data from 15 studies 56, 64, 67, 68, 75, 77, 88-96 published between 1985 and 2007 suggested 
a dose-response relationship according to severity of diarrhoea, based upon the retention 
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value of the SeHCAT test, and to treatment with a bile acid binder: response to colestyramine 
occurred in 96% of patients with <5% retention, 80% at <10% retention and 70% at <15% 
retention 69. 
 
Colesevelam is a new bile acid sequestrant that binds bile acids with a higher affinity than 
colestyramine or colestipol, as it forms a polymeric gel in the gastrointestinal tract.  It is 
available in tablet form and hence bypasses the unpleasant taste of colestyramine and 
making it more acceptable 97.  In a recent retrospective study comparing colesevelam to 
colestyramine, colesevelam appeared to be effective in patients who had failed treatment 
colestyramine 98. 
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1.7.5 Research into mechanisms of BAD. 
 
The pathogenesis of so-called Primary BAD has not been clearly understood since the 
characterisation of this condition in the 1970’s; recent research has focused on discovering 
the molecular mechanisms predisposing to this condition.   These have to explain an excessive 
bile acid loss into the colon, a reduced SeHCAT retention, and raised bile acid precursor levels.  
A number of mechanisms have been proposed: 
 
1) a defective ileal BA transport system 99 
2) a reduced length of the segment capable of functional bile acid uptake, or a reduced 
contact time due to a primary increase in small intestinal motility 100 
3) an increase in bile acid pool size 65 due to disordered negative feedback regulation of 
bile acid synthesis 101. 
 
 
1.7.5.1 Defective Ileal enterocyte bile acid transport 
 
Originally it was widely believed that a defective BA transport capacity may be the causative 
factor of BA diarrhoea.  Heubi et al demonstrated in a family of two brothers an impaired ileal 
uptake of bile acids 102. In 1997, Oeklers et al. demonstrated a mutation in the ASBT gene 
(SLC10A2) in this family 99. This however is now known to be a rare congenital cause of PBAD, 
as ASBT mutations were not found to be commoner in a series of 13 patients with adult onset 
bile acid diarrhoea than in controls 103. ASBT polymorphisms were found in both population 
groups and did not appear to affect ASBT function. In this study Montagnani et al in 2006 
studied a family with adult PBAD in three consecutive generations to evaluate whether there 
was an association of PBAD with inherited mutations affecting the ASBT. It was clearly 
demonstrated that there was no segregation of the bile acid malabsorption phenotype with 
polymorphisms in the ASBT gene 104. 
 
Mutations in FABP6 gene encoding IBABP have also been studied and were no more common 
in patients with PBAD than in controls 105. IBABP may not in fact be that crucial an element in 
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bile salt malabsorption as FXR knockout mice that are deficient in IBABP did not appear to 
have impaired bile acid absorption 24.  
 
When ileal RNA and cDNA were prepared from patients with chronic diarrhoea and control 
subjects, no significant difference in mean expression of any of the transporter transcripts 
including ASBT, IBABP, OSTα and OSTβ, was found in terminal ileal tissue in patients with 
PBAD compared with controls.  There was however evidence to suggest there could be 
differences in the regulation of expression of OSTα by the nuclear bile acid receptor FXR 105. 
Polymorphisms in the baso-lateral membrane transport complex (organic solute transporters, 
OST and OST) have not been studied. 
 
Further review of the literature, indicates that there may be no overall transport defect in 
PBAD.  Uptake of taurocholate into ileal mucosa biopsies is in fact somewhat higher than in 
controls 78.  Transport studies looking at taurocholate uptake into brush border vesicles from 
terminal ileal biopsies in 10 patients with PBAD also suggested that there was no impairment 
of bile acid uptake; in fact transport was significantly higher 106, 107.  These studies are 
counter-intuitive for a condition described as "malabsorption" but they encourage the 
suggestion that alternative mechanisms need to be considered. 
 
 
1.7.5.2 Rapid small bowel transit and other theories 
 
The possible role of rapid small bowel transit in patients with BAD has been proposed to 
explain the pathophysiology. Rapid transit would result in a reduced time for reabsorption of 
bile acids in the terminal ileum. In one study there was no correlation between SeHCAT and 
small bowel transit time detected with hydrogen breath test after lactulose ingestion and 
with Tc99 m-HIDA 89.  Rapid small bowel transit was demonstrated however in PBAD patients   
and this was more obvious in women than men 100. 
 
A rapid small bowel intestinal transit may result in an increased bile acid enterohepatic cycling 
frequency, which would result in greater loss of bile acids into the faeces and a reduction in 
SeHCAT retention. Figure 8c shows that an increase in bile acid cycling from 4 to 6 times a day 
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will result in an increased loss of bile acids into the faces and a reduction in SeHCAT 
retention53.  
 
 
 
 
 
Figure 8:  Effects of specific changes affecting the enterohepatic circulation of bile acids on 
calculated SeHCAT retention and faecal bile acid loss 53.  
 
SeHCAT retention (open symbols, left axis) and cumulative faecal bile acid loss (closed 
symbols, right axis) are shown over 7 days.  The line shows 10% SeHCAT retention.  (a) 
Typical normal values,  (b) Effects of reducing bile acid absorption on each cycle from 95% 
to 90%,  (c)  Effects of increasing number of cycles to 6/day from 4/day,  (d)  Effects of 
increasing the total bile acid pool size from 2g to 2.8g.  Absorption is increased from 1.9g to 
2.6g; the fractional absorption decreases slightly from 95% to 93%.   
A 
D C 
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This  shorter time for reabsorption would result in a defective net uptake of bile acids, but 
would not be consistent with an important study showing an enlarged bile acid pool in 
patients with primary BAD 65. Figure 8d shows that a larger pool, with unchanged cycling 
frequency, and an increased absolute ileal bile acid absorption  can result in a reduced 
SeHCAT retention and increased faecal bile acid output 53. 
 
Other studies have shown that the migrating motor complex phase III induced jejunal secretion 
may be upregulated in BAD patients which may overload reabsorption capacity in the colon 108. 
 
An autoimmune phenomenon has also been postulated, similar to coeliac disease, with the 
ileum as a target organ and resultant villous atrophy. This was seen in one study with very 
small numbers of patients 109, but has not been confirmed by other studies; the current 
definition of idiopathic/primary BAD requires there to be a morphologically normal ileum. 
 
In some studies the onset of BAD has been suggested to have been triggered by a 
gastrointestinal infection but there have are no definite associations with infectious agents or 
changes in inflammatory cells 110 . 
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1.7.5.3 New emerging mechanisms 
 
Recently a mechanism involving increased bile acid losses as a consequence of defective 
feedback regulation is becoming established.   As elucidated earlier, Van Tilburg and 
colleagues 65 published data in 1992 showing the mean BA pool size was larger in patients 
with primary BAD than controls.  This and other results they found are included in Table 5, 
which shows a doubling of faecal bile acid loss and of the bile acid pool size.  These two 
measurements showed a highly significant correlation.  The SeHCAT retention was reduced 
(roughly equating to 10% 7-day retention vs. 15% in controls). Absorption of bile acids in the 
ileum may be somewhat increased 107, but with greater increases in BA synthesis and 
secretion, BAs spill over into the colon and faeces. 
 
 
  Controls  Primary Bile Acid 
Diarrhoea (PBAD) 
Van Tilburg et al.  (n=8) (n=8) 
 Faecal BA loss (mmol/day) 1.0  0.1 2.5  1.0 * 
 BA pool size (mmol) 3.7  1.0 7.0  4.4 * 
 75SeHCAT retention (half-life 
in day) 
2.6  0.7 2.1  1.1 
Walters et al.  (n= 19) (n=13) 
 C4 (ng/ml) 17  9 91  74 * 
 FGF19 (pg/ml) 268  145 103  53 * 
 
Table 5:  Reported bile acid kinetics and FGF19 in patients with Primary bile acid diarrhoea 
and controls 53. Data taken from references 65,  101.  Means  SD are shown; * p < 0.05. 
 
High transintestinal and transhepatic BA flux suppresses BA synthesis in normal subjects.  
However in PBAD, synthesis is increased as shown by the raised values of the BA precursor 
C4.  This has been shown repeatedly 77, 101 and was thought to compensate for the increased 
BA loss due to the "malabsorption".  But with an increased BA pool, this may in fact be the 
primary disorder. 
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The feedback regulation of the enterohepatic circulation and hepatic BA synthesis is now 
thought to be mediated by FGF19 which is the human homologue of FGF15 in mice.  Data has 
accumulated to indicate this has an important hormonal role in suppressing hepatic bile acid 
synthesis.   As discussed, FGF19 in the ileum is a BA responsive gene, transcriptionally 
activated via FXR, which is synthesised in the absorptive enterocytes 32.  Mice with ASBT -/- 
have watery diarrhoea which responds to FGF15 treatment 111, and so resemble PBAD.    
 
GW4064, a synthetic FXR agonist, increases FGF15 transcription more than any other ileal 
gene 112 and in FXR -/- mice FGF15 production was reduced 32. 
 
In a more recent study, anti FGF19 treatment to cynomolgus monkeys demonstrated dose 
related toxicity, but also resulted in severe diarrhoea. A fully humanised anti-FGF19 antibody 
that binds to FGF19 and effectively blocks binding of FGF19 to FGFR4 was used and was 
shown to increase CYP7A1 and BA efflux transporter gene expressions; in addition elevated 
bile acid transporters (IBAP, OSTα & β) gene expression in ileal tissues was seen. There was an 
increase in faecal total BAs with accompanied severe diarrhoea 113. 
 
Recent data has shown that patients with PBAD have levels of FGF19 which are about 50% of 
controls, and this level correlates inversely with BA synthesis as measured by C4 (Table 5) 101.  
In this research by Walters group published in 2009, 17 patients had chronic watery diarrhea, 
and 13 of these patients had SeHCAT test retention of less than 8% at one week; they were 
compared with controls without diarrhoea. Fasting FGF19 and C4 levels were measured. 
Median C4 was significantly higher in the patient group, (51 versus 18ng/l). There was a 
negative correlation between C4 and FGF19, and median FGF19 was found to be significantly 
lower in patients compared with controls, (120 versus 231pg/l) 114. This was a retrospective 
series with small numbers, but “it appears to be a major advance in the further understanding 
of BAD115”.  
 
Hence the disrupted feedback control by FGF19 of BA synthesis results in a cycle of excessive 
BA production, incomplete absorption, and excess faecal loss causing diarrhoea, Figure 9.  The 
precise nature of the defect in the enterocyte that leads to impaired FGF19 secretion is 
unclear and needs further research.  Differing levels of bile acids in the enterocyte might 
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produce different transcriptional signals on the BA/FXR-responsive genes, with greater 
stimulation of OST than FGF19, for instance.  Previous work has indicated subtle differences 
in the relationships of different transcripts in the ileum 105. 
 
 
 
 
 
 
 
 
 
                            
  
 
 
 
Figure 9a          Figure 9b 
 
Figure 9a: Normal bile acid synthesis, enterohepatic circulation and FGF19 feedback. 
Figure 9b: Reduced FGF19 excretion, increased hepatic BA synthesis. Bile acids are shown in 
yellow and the size of the arrows reflects their concentrations; FGF19 is shown in purple 116.
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 1.8 Genetic aspect 
 
The mechanism that leads to the impaired deficiency in FGF19 secretion by the ileum is 
currently not understood. Recent work has demonstrated the importance of genetic variation 
in the control of BA levels.  
 
 
1.8.1 FXR polymorphisms 
 
Overall FXR maintains low bile acid levels in enterocytes and also in hepatocytes. In theory, 
FXR variants could therefore affect transcription of FGF19 and other enterocyte-expressed 
FXR target genes differently. A previous study found differences in regulation of expression of 
OSTα by transcription factors such as FXR between controls and PBAD patients  
117 . Furthermore, FXR knock-out mice have been shown to resemble PBAD patients with an 
increased BA reabsorption and an enlarged BA pool size 24. It is possible that polymorphisms 
in the FXR gene could confer susceptibility to PBAD.  
 
The FXR gene, NR1H4 codes for four isoforms – FXRα1 and FXRα2 have a different N-terminus 
to isoforms FXRα3 and FXRα4. α1 and α3 differ from α2 and α4 in that they contain an 
additional 4 amino acid (MYTG) insertion in the hinge region of the receptor (exon 5) as a 
result of alternative splicing 118. The main isoforms expressed in the intestine are FXRα1 and 
FXRα2. The FXR gene that codes for these isoforms is found on chromosome 12 and consists 
of 11 exons, with the translation initiation site located in exon 3.  
 
Two studies have described several FXR variants in the general population and in intrahepatic 
cholestasis of pregnancy (ICP) cases 118, 119. Most of the variants identified in these studies 
were found to be rare with low genotypic frequencies (<1%), except one single nucleotide 
polymorphism (SNP). The -1g>t polymorphism was found to be relatively common with 
population allele frequencies of 2.5-12% (Chinese (12.1%) and African (3.2%) populations 
having much higher frequencies than Caucasians (2.5%) 118). This polymorphism was also 
found to be associated with reduced FXR target gene expression in the liver. This SNP has not 
been studied in patients with PBAD. This SNP rs56163822 is found in exon 3 and results in a –
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1g>t substitution in the nucleotide immediately before the translation initiation site (ATG 
codon). It is a non-coding SNP and functional analysis of the –1g>t variant in the ICP study 
found that it causes a reduced translation efficiency, therefore leading to reduced levels of 
FXR protein 119. This could in theory result in reduced expression of FGF19 and therefore low 
levels of FGF19 resulting in a phenotype resembling PBAD. 
 
A further variant identified in the ICP patients was M173T which was found to have a 
population allele frequency of up to 4.1% 119. The M173T variant is positioned in the DNA-
binding domain of FXR in the second zinc finger. This SNP rs81766060 was shown to have a 
significantly reduced ability to activate transcription of FXR via the BSEP and IBABP promoters 
compared with wild-type FXR. It has been proposed that this variant may predispose to ICP 
due to its transcriptional effects on FXR and therefore may be associated with other disorders 
that utilise FXR. 
 
 
1.8.2 Klotho β polymorphisms 
 
Knockout mouse data showing that loss of Klotho β function leads to an increased bile acid 
pool size and a markedly elevated faecal bile acid excretion 120.  
 
A recent study tested 15 common SNPs from 7 genes involved in BA homeostasis and 
associated a Klotho β variant (SNP rs17618244) to mediate protein stability and associate it 
with accelerated colonic transit in IBS predominant diarrhoea patients.  
 
Previous work by this group looked at the use of chenodeoxycholate in females with IBS and 
found colonic transit and ascending colon emptying were significantly increased compared 
with placebo 121. Stool frequency was found to be increased and stools were looser. There 
was a significant association between fasting C4 levels and bowel transit, although no 
association with FGF19 was found. It was found that a SNP in the FGFR4 gene was associated 
with increased transit with the 2 different doses of CDCA administered. The authors 
concluded that patients with this genotype may be more susceptible to the effects of 
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endogenous BAs. An association was identified with a SNP encoding Klotho β with a different 
effect of the two doses on the participant subtypes.  
 
 
1.8.3 FGF19 polymorphisms 
 
Two common SNPs rs948992 and rs1789170 in the FGF19 gene have mean allele frequencies 
of between 10 and 49%. No previous studies have looked at this candidate SNPs in primary 
BAD population. 
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2.1 Hypothesis and Aims 
 
The hypothesis for the basis of this thesis is that disordered FGF19 levels occur in patients 
with BAD compared with controls and is not affected by chronic diarrhoea. Disordered FGF19 
signalling can produce excessive bile acid synthesis, colonic loss and chronic diarrhoea, and in 
the absence of terminal ileal dysfunction, is diagnosed as primary BAD. We hypothesised that 
patients with BAD diagnosed by SeHCAT and/or C4 measurements would have a breakdown 
(or disruption) of the inhibitory feedback of bile acid synthesis by FGF19 and have reduced 
levels of serum FGF19. Normal levels would be found in group of patients with chronic 
diarrhoea without the diagnosis of BAD.  
 
This may further the understanding of the cause and effect underlying the process of bile acid 
loss into the large intestine.  
 
2.2 Aims 
 
The main attention for this research is the focus on FGF19 and its role into the mechanism of  
BAD. The main aims of this research project are:  
 
1. To recruit patients prospectively with unexplained chronic diarrhoea and obtain 
samples from blood and ileal mucosa (Study 1). 
 
2.   To characterise the above cohort with SeHCAT retention tests and define patients into 
BAD (primary and secondary) and control diarrhoea groups (Study 1). 
  
3. To measure serum FGF19, serum bile acids and the precursor (C4) measurements 
under defined conditions from the prospective group and optimise sampling 
conditions (Study 2). The relationships of FGF19 with other factors including age, 
gender, obesity and response to treatment will be examined.  
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4.  To determine whether FGF19 can be used as a tool in the diagnosis of BAD and to 
determine its sensitivity and specificity to known validated tests for BAD (Study 1) in 
the prospective group and also compare this to a retrospective cohort (Study 5). 
 
5. To determine whether there are any changes or indicators in routine bloods, 
particularly in lipid profiles, liver function tests and vitamins in patients with BAD 
(Study 1). 
 
6.  To determine the effectiveness of treatment with bile acid sequestrants in patients 
with BAD (Study 1). 
 
7.  To identify patterns and variations of FGF19 levels during the day in patients with 
Primary BAD and compare and expand on previous similar work performed in a pilot 
study in 2007 101 (Study 3). 
 
8. To investigate the effects of purgatives used for colonoscopy preparation (Study 4) on 
FGF19.  
 
9. Additional projects include examining a cohort of patients who have short bowel 
syndrome. Information gathered regarding FGF19 levels from this study will contribute 
to the understanding of the behaviour of FGF19 in patients whom have had small 
bowel surgery (Study 6). 
 
10. To examine the effects of bile acid sequestrants on FGF19 levels in healthy individuals 
(Study 7).  
 
11. To start to investigate genetic differences in genes regulating bile acid metabolism in 
patients with primary bile acid diarrhoea (Study 8). 
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3. Materials and Methods 
 
3.1 Study 1: FGF19 in patients with chronic diarrhoea 
 
3.1.1 Patient Recruitment 
 
This study forms the main part of the research and patients were recruited prospectively and 
divided into two main groups. The underlying symptom that these patients had was chronic 
diarrhoea, which is defined as bowel frequency exceeding 3 stools per day for more than 3 
months. 
 
Patients with chronic diarrhoea were recruited and consented from three different sites 
within Imperial Healthcare Trust (Hammersmith, Charing Cross, and St. Marys Hospital). In 
total 114 prospective patients were recruited from this Trust. In addition, collaboration with 
Gastroenterologists from Rotherham General Hospital (RGH) added a further 38 patients to 
the overall cohort. In general patients were identified from Gastroenterology outpatient 
clinics, nuclear medicine departments for patients referred for SeHCAT testing, and from the 
endoscopy units when patients were referred for colonoscopy; these patients had been 
referred from outpatient clinics for routine investigation for chronic diarrhoea. Overall 152 
patients have been recruited in this manner. 
 
Consented patients had fasting blood samples taken when attending for routine 
investigations for work up for chronic diarrhoea that would normally require fasting. These 
investigations included glucose hydrogen breath tests (for small bowel bacterial overgrowth, 
lactose intolerance) and SeHCAT tests.  
 
A chronic diarrhoea proforma was developed (see appendix 2) and completed when patients 
attended for blood sampling as above; patient details were recorded including demographics, 
and clinical history (past medical and surgical history, family history, drug and social history 
including smoking, alcohol intake per week and coffee intake per day); chronic diarrhoea 
characteristics including stool frequency during the day and night, duration of chronic 
diarrhoea, stool consistency according to a Bristol Stool Chart, and associated symptoms were 
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collated. The investigations such as routine blood tests, stool tests for microbiology or faecal 
elastase (pancreatic function test), SeHCAT result, colonoscopy and biopsy findings, glucose 
and hydrogen breath tests for lactose intolerance and small bowel bacterial overgrowth 
respectively and radiology tests (barium studies, computerised tomography (CT) scans, 
ultrasound scans) were also recorded as part of routine outpatient tests for chronic 
diarrhoea. Records of follow up and treatment outcomes were also noted.  
 
When patients attended for routine colonoscopy with either a history of chronic diarrhoea, 
with or without a SeHCAT test result, patients were consented for terminal ileal (TI) biopsies 
for research in addition to routine histology biopsies; biopsies taken from patients were to be 
used later for RNA preparation and quantification; it was apparent in the latter stages of the 
research that this work was beyond the capacity of this MD research. 
 
The research has been approved by the Hammersmith Research Ethics Committee as well as 
Ethics Committee at Rotherham General Hospital. 
 
 
3.1.2 Characterisation of patients 
 
BAD may result from several potential causes and therefore this group of new patients were 
carefully identified and other causes excluded. 
 
The aim was to recruit from the above sites prospectively over the course of 1.5 years with a 
shorter period of patient recruitment at RGH due to later collaboration during the course of 
the clinical study. All patients presenting with chronic diarrhoea, who agreed to be included in 
the study, were subdivided into groups including (1) those with primary BAD,  (2) those with 
diarrhoea secondary to other causes of bile acid malabsorption (e.g. patients with short 
bowel syndrome, lactose intolerance, post cholecystectomy, Crohn’s disease), and (3) 
patients with diarrhoea and normal SeHCAT retention. Fasting blood samples and biopsies 
were taken from these groups. A few healthy controls without diarrhoea or gastrointestinal 
disease were also recruited from our research group at Hammersmith Hospital, for studies 
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involving optimising of conditions for blood sampling and also in the study of the effects of 
bile acid sequestrant on FGF19 levels.  
 
BAD patients were defined by using tests that are well established and validated. This was via 
measurements of bile acid retention (SeHCAT), as discussed before. All patients underwent 
SeHCAT testing. Further validation of BAD was performed on samples collected by measuring 
the serum intermediatory molecule, C4, as a marker of bile acid synthesis.  
 
Dr Gordon Brydon at the Western General Hospital in Edinburgh measured C4 through an 
HPLC method, in a pilot study of blood levels of FGF19, and has confirmed that C4 is elevated 
in BAD patients. Dr Brydon and his successor Kathleen Kingston agreed to continue and 
collaborated with measuring C4 levels in serum samples collected in this study. 
 
Collaboration was also sought with Dr John Meek at the Biochemistry Department at 
Hammersmith Hospital to measure total bile acids in the serum that was collected.  
 
 
3.1.3 Sample collection 
 
Venous blood samples taken from each patient or control in the various studies were 
collected in a serum separator tubes which were centrifuged at 3000 rpm for 12 minutes to 
obtain serum. The serum was then pipetted into aliquots and stored at -20 0C ready to be 
assayed. 5mls of blood was also collected for DNA in plastic (EDTA) tubes to prevent blood 
from clotting and were frozen at -20 0C for DNA extraction at a later date. 
 
Up to 6 terminal ileum biopsies are collected at the time of colonoscopy. They are collected in 
RNA later (Ambion, Huntingdon, Cams, UK) and stored at -20 0C as per product instructions.  
 
 
3.1.4 Serum analysis 
 
3.1.4.1 FGF19 assay 
57 
 
A commercial enzyme-linked immunosorbent assay (ELISA) kit, employing a sandwich enzyme 
technique was used to measure the quantity of FGF19 in serum samples (FGF19 Quantikine 
ELISA kit, Cat. No. DF1900; R&D Systems, Minneapolis, MN, USA), following the 
manufacturer’s instructions. This testing kit has been previously used in the previous pilot 
study 114. 100µl samples of serum were assayed in duplicate. The assay is linear between 16 
and 1000pg/ml. The intra-assay and inter-assay coefficients of variance are about 4-6% 
(manufacturer’s data, confirmed in the laboratory).  All assays were run with mid pool 
samples (previously collected with known FGF19 levels) to ensure consistency and observe 
the inter-assay variation.  
 
 
3.1.4.2 C4 assay 
 
Serum levels of C4 were analysed by high performance liquid chromatography (HPLC) 
following solid phase extraction (SPE) of C4 from individual serum samples. This has been 
previously described as above. 
 
 
3.1.4.3 Serum total bile acids 
 
Total bile acids were measured by an enzymatic colorimetric method using 3-α-
hydroxysteroid dehydrogenase, (Ref. no. 6K9001, Sentinel Diagnostics, Milan, Italy).  
 
 
3.2 Study 2: Optimization of sampling conditions 
 
3.2.1. Effect of freeze/thaw and type of blood collecting tubes on FGF19  
 
To minimise the need for repeated freezing and thawing of samples, aliquots of a serum 
specimen were stored in several small containers. It is, however, often necessary to use 
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plasma or serum that has undergone one or more freeze-thaw cycles. It is important to 
ascertain the validity of data obtained from these specimens. 
 
The effect of repeat thawing and freezing on the measurement of FGF19 levels was 
determined. We hypothesised that serum FGF19 levels would diminish on subsequent freeze-
thaw cycles.  
 
An additional series of fasting blood samples were collected from the three control subjects 
used for stability testing as below; serum was extracted and frozen at 0 hours. An aliquot of 
these samples underwent 2 repeat defrosting and refreezing cycles. These samples were then 
frozen at -20⁰C. The samples were not thawed again until the time of the assay, thereby 
completing the third freeze-thaw cycle. All samples were assayed together by ELISA on a 
single assay plate to reduce any inter-assay variation.  
 
The effect of using different blood collecting tubes on FGF19 levels was also studied. Blood 
was collected in an Ethylenediaminetetraacetic Acid (EDTA) tube (purple top), serum gel 
separator (yellow top), and plain red tubes. Samples were centrifuged and sera extracted and 
frozen at -20 0C, to be assayed latter. 
 
3.2.2: Short and long term stability of FGF19 
 
The aim of this study was to assess whether levels of FGF19 in serum vary according to the 
time when a sample is taken from the patient to time of extracting serum and freezing. We 
hypothesised that serum FGF19 levels would be stable over a short period of time i.e. over a 
matter of hours, but not stable over a matter of days from the time the blood sample was 
initially collected and left at room temperature to the time the serum was extracted and 
frozen in preparation for assaying.  
 
3.2.2.1 Short term stability testing 
 
Three control subjects were recruited who did not have chronic diarrhoea and no previous GI 
disease and were otherwise healthy.  Subjects were fasted overnight; 3 blood samples 
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(collected in serum gel separator tubes) were taken at 0hrs. The 1st sample was spun down 
and serum extracted and frozen at -20 0C. The other 2 blood samples were left at room 
temperature and subsequent preparation of blood and freezing of samples were conducted 
at 3hrs and 6hrs. 
 
3.2.2.2 Long term stability testing 
 
Fasting blood samples from 4 control patients were collected. 5 samples from each subject 
were taken and kept at room temperature and processed at various times over 48 hours. 
Serum was extracted and frozen to be subsequently assayed for FGF19.  
 
 
3.3 Study 3: Variation of FGF19 levels during the day in patients with Primary 
BAD: Day series 
 
Patients with primary BAD who had previously consented were contacted and invited to 
attend for a series of blood tests throughout the day to determine the variation of FGF19 
when fasted and subsequent stimulation with standard meals. A total of 11 patients 
consented to this study. 
 
Patients in groups of 2-3 at a time presented to a Research Investigations Day Ward at 
Hammersmith Hospital at 08.30 am having fasted from midnight. Patients were also 
instructed to stop taking their bile acid sequestrants 1 week prior to the appointment. 
Patients had an indwelling venous cannula inserted on arrival and their first fasting blood 
sample taken in a yellow serum separator tube between 8.30 am and 9.00 am. At 09.00 am 
patients were then supplied with a standard/typical breakfast of cereal with milk, croissant 
with butter and jam, fruit, orange juice and tea or coffee. Blood sampling from the cannula 
was then taken every 1.5 hours i.e. 10.30 am and 12.00am. At this point patients were 
administered a standard/typical lunch of a sandwich, packet of crisps, fruit, yoghurt (full fat), 
and a glass of juice. A further 2 blood samples at 13.30 and 15.00 were taken. Patients were 
then discharged and allowed to resume their medication for BAD. Overall this allowed 
determination of the important peaks of FGF19 levels compared to the troughs levels.  
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The content and quantity of the meals had been standardised for all the patients and had 
been used previously in a pilot study. Blood samples taken at each time point were 
immediately centrifuged and serum collected, aliquoted and stored at -20 0C for later analysis.  
 
 
3.4 Study 4. Effect of bowel preparations for colonoscopy on FGF19 
 
The aim of this sub-study was to ascertain the effect of bowel preparations commonly used 
for colonoscopy on the serum levels of FGF19. We hypothesised that FGF19 levels would be 
diminished following bowel preparation due to the increased bowel transit time.  
 
Patients whom were waiting for a SeHCAT or had the test previously and were also waiting to 
have a colonoscopy performed as part of their routine investigation for chronic diarrhoea 
were recruited and consented to have fasting blood samples taken at colonoscopy and at 
another fasting point without bowel preparation. This would either be at the time of SeHCAT 
or for a breath test, for example.  Fasting FGF19 levels were then compared in patients who 
had a baseline fasting level to levels taken at the time of colonoscopy with bowel preparation. 
The different bowel preparations were also noted. The commonly used bowel preparations 
used at Hammersmith Hospital are either citramag and senna combination or Klean prep. 
Overall 21 patients with chronic diarrhoea had simultaneous sampling. 
 
 
3.5 Study 5: FGF19 correlation with C4 values from a retrospective cohort of 
patients from Scotland with chronic diarrhoea 
 
Previous studies have indirectly validated C4 as a test for diagnosing BAD by simultaneous 
assessment of C4 and SeHCAT 77. The diagnosis of BAD in Edinburgh and surrounding areas of 
South East Scotland is made on the basis of C4 as SeHCAT testing is not available at the 
Western General Hospital in Edinburgh. 
 
Patient Group No Estimated 
median SB 
length post 
ligament of 
Treitz (cm) 
SBS 1 Without distal ileum or               
            colon in continuity 
12 90 
SBS2   distal ileum and/or    
            colon in continuity 
            (distal ileum included) 
11 
 
(2) 
35 
Healthy controls 14 - 
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Fasting blood samples had been collected from consecutive patients in and around Edinburgh 
between July 2008 and March 2009, with chronic diarrhoea referred as part of a routine 
clinical referral service for C4 measurements. These patients have been included in a larger 
group recently reported 122. Subjects were asked to avoid alcohol for at least 12 hours before 
the test and were not taking bile acid sequestrants. Serum was separated and samples were 
stored at -20 0C within 24 hours for the C4 assay. 
 
Group 1 patients (n=119) were referred for investigation of chronic diarrhea and had normal 
C4 levels (reference range 4-28 ng/ml).Group 2 (n=139) were diagnosed as having possible 
BAD based on high C4 measurements (≥28 ng/ml), determined using an HPLC method.  This 
group included patients with any of the possible causes of BAD (Type 1, 2 or 3 BAD). Serum 
FGF19 was measured on both these sample groups by ELISA. The diagnosis leading to referral 
was recorded to clarify BAD Types. Data was analysed to compare the relationship between 
FGF19 and C4 on both these groups and in the three Types of BAD. 
 
C4 measurements were determined using an HPLC method with a prior solid phase extraction 
as previously described 123, 77.  Although the original reference range quoted was 5-35ng/ml 77  
this was subsequently revised, using a new commercial standard from Steraloids (Newport, 
RI, USA).   
 
 
3.6 Study 6: FGF19 in patients with Short Bowel Syndrome  
 
Loss of absorption of bile acids from the distal ileum due to extensive resection of the 
intestine, causing short bowel syndrome (SBS), will add to symptoms including diarrhoea. We 
hypothesized that disordered production of FGF19 would occur in patients with SBS.  
 
Blood samples were available from 23 patients with SBS collected from St Marks Hospital, 
London. These were subdivided into two groups. SBS1 (n=12) contained SBS patients without 
distal ileum or colon, and the estimated median small bowel length post ligament of Treitz 
was 90cm. SBS2 (n=11) had SBS patients with colon in continuity with an estimated median 
small bowel length of 35cm, with distal ileum included in 2 of these patients. The underlying 
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diagnosis leading to SBS was recorded (Table 6). Healthy controls (n=14), were also studied. 
Fasting venous samples had been collected, plasma separated and stored. Other hormones 
have been determined previously on these samples. FGF19 levels were subsequently 
measured. 
 
Underlying diagnosis leading to SBS 
 
No. of patients 
Crohn’s disease 7 
Mesenteric infarction 12 
Volvulus 3 
Other 1 
 
Table 6: Underlying diagnosis leading to SBS in patients collected from St Marks Hospital 
 
 
3.7 Study 7: Effect of Colestyramine withdrawal on FGF19 in healthy patients 
 
Studies have shown that levels of FGF19 remain low whilst on bile acid sequestrants 124. We 
hypothesised that levels would start to rise after colestyramine was stopped and the aim was 
to determine the variation of FGF19 levels over a period of time, in days, when levels would 
return to baseline.  
 
Two control subjects were recruited who did not have chronic diarrhoea and no previous 
history of gastroenterological disease and were otherwise healthy. Fasted blood samples 
were taken on first day to measure baseline FGF19 levels. 4 grams of colestyramine (one 
sachet) was administered at night time (normal dosing regimen for patients on treatment for 
BAD) and was taken for a period of 14 days. Fasting blood samples were collected periodically 
during this 14 days and serum was extracted and frozen at -20 0C.  
 
Further fasting blood samples were taken on the subsequent 8 days after stopping 
colestyramine to ascertain the length of time in days, it takes for FGF19 levels return to 
baseline. FGF19 levels were performed on serum samples. 
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3.8 Study 8: Genotyping study 
 
3.8.1 Subjects 
            
The case group consisted of patients with the diagnosis of Primary bile acid diarrhoea only, 
who were diagnosed on the basis of an abnormal SeHCAT retention test of less than 15%, 
with no evidence of other diseases, i.e. Type 2 BAD. Blood samples were collected from 
patients as previously described. The control group consisted of those patients with normal 
SeHCAT retention (above 15%) together with those with Type 1 and Type 3 BAD.  
 
Additionally, blood samples collected from previous studies looking at primary BA diarrhoea 
patients were also utilised. These included 22 samples from patients recruited retrospectively 
at the Royal Bolton Hospital in 2008 and 13 patients recruited in a retrospective study in 
Hammersmith Hospital in 2008. In total the case control study consisted of 76 PBAD patients 
and 92 controls. These blood samples were frozen at -80  C in EDTA tubes until DNA 
extraction was carried out.  
 
Ethical approval was obtained from the Hammersmith and Queen Charlotte Hospital’s 
Research Ethics Committee and all participants gave informed consent. 
 
3.8.2 DNA extraction  
 
Genomic DNA was extracted from blood obtained from patient using the QiAmp DNA mini kit 
(Qiagen, CA, USA), according to the manufacturer’s protocols. This kit uses a fast spin-column 
procedure where DNA binds specifically to the QiAmp silica-gel membrane. DNA was isolated 
from leukocytes in 200µl of whole blood. The initial step consisted of lysis of the cells 
releasing the DNA, which was loaded onto individual spin columns, followed by two wash 
steps to eliminate contaminants. A final elution step with a specific buffer solution led to the 
extraction of 200µl of pure DNA. This was stored frozen at -20  C to be used later.  
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3.8.3 DNA Purity and Quantity 
 
The DNA samples were analysed on the NanoDrop ND-1000 spectrophotometer to determine 
purity and concentration (ng/µl). The ratio of absorbance at wavelength 260nm and 280nm 
(A260/A280 ratio) was measured to determine purity with an accepted range between 1.7-
1.9. Any DNA samples outside this range were discarded and extracted again. All samples 
were diluted with the buffer solution to a standard concentration between 3- 25 ng/µl.  
 
3.8.4 Genotyping 
 
The samples were genotyped for the SNP using a TaqMan allelic discrimination assay on an 
Applied Biosystems StepOnePlus Real-time PCR machine (Applied Biosystems, Foster City, CA, 
USA). TaqMan Assays are pre-developed reagents custom made for the specific SNP of 
interest. They consist of two sequence-specific primers (forward and reverse) to amplify the 
polymorphic sequence of interest and two TaqMan probes labelled with a fluorescent dye for 
distinguishing the two alleles.  Polymerase chain reaction (PCR) was performed on 96-well 
plates using components including 7.5µl TaqMan® Genotyping Master Mix (2X), 0.375 µl SNP 
Assay Mix (40X), 6.125 µl DNase-free water and 1 µl Genomic DNA (3-25ng) per well. The total 
reaction volume therefore was 15 µl per well. A negative control (1µl pure water instead of 
DNA) and where possible a positive control (heterozygous for SNP) were also used for each 
experiment. Standard PCR conditions were used: 95  C for 10 minutes, followed by 40 cycles 
of amplification at 95  c for 15 seconds and 60  c for 1 minute, and finally 60  c for 30 seconds. 
 
The fluorescence signals for each plate were analyzed using StepOne software version 2.0.1 
and genotype calls assigned to each sample/individual. 
 
Two common SNPs in the FGF19 gene were analysed as well as 2 SNPs (M173T, and -1g>t,) in 
the FXR gene. A SNP in Klotho β and a further SNP in the OSTα gene was also studied.  In total 
6 SNPs were analysed as shown in Table 7. The SNPs chosen for each candidate gene were 
known to have a higher mean allelic frequency in other population groups. 
 
 
65 
Gene SNP rs ID Alleles Chromosomal 
Location 
MAF % Location 
FGF19 rs948992 C/T 11:69513338 49 utr-3’ 
FGF19 rs1789170 G/A 11:69509343 10-25 3’-flanking 
FXR : 
1g>t 
rs56163822 G/T 12:100887101 2.4-12 5’-utr 
FXR: 
M173T 
rs61755050 T/C 99450439 0.8 missense 
Klotho β rs17618244 A/G 39124924 20 missense 
OSTα rs939885 A/G 3:195955762 50% missense 
 
Table 7: SNPs analysed for genotyping study. MAF = mean allele frequency. 
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 3.9 Statistical analysis 
 
All data was analysed in Microsoft Excel® using WinSTAT®. Non-parametric Mann-Whitney or 
Wilcoxon paired tests were performed to assess statistical differences in C4 levels and FGF19 
data with significance defined as p<0.05. Results were displayed as median ± SEM. 
Spearman’s Rank coefficients were used to assess the relationship between different 
variables. Receiver Operating Characteristic (ROC) analyses were performed using SigmaPlot 
12 (Systat Software, Hounslow, UK).  
 
Allele frequencies were calculated for the cases and control groups. The Fishers exact test 
was used to look for a significant difference in the frequency of the SNP between cases and 
controls. Odd Ratios (ORs) were calculated with 95% confidence intervals (CI); again, p <0.05 
was considered statistically significant. 
 
3.10 Power calculations 
 
A previous pilot showed a significant statistical difference (p<0.01) in FGF19 levels between 
the patient group of PBAD and a healthy control group 114. The mean and standard deviation 
for FGF19 has been used to calculate numbers for this prospective work. A two-sampled T 
test was used; to achieve a power of 80% to detect a difference at the p<0.05 level, and a true 
difference of mean at 0.5 (referring to results of the pilot study), 64 patients would be needed 
in each group. (http://www.stat.uiowa.edu/~rlenth/Power).  
 
With regards to the genomic studies a power calculation was performed on the first SNP 
analysed to estimate the sample size needed to detect a significant difference. Based on 
findings in the previous studies, it was assumed that a population prevalence of 2.5% for the 
G-1T SNP and a 4-fold increase in the primary BA patients (10%). Therefore, to detect a 4 
times increase in frequency with 80% power, 175 subjects would be required (χ² = 9.072, p = 
0.0026). To achieve this number, data on healthy Caucasian controls from a previous ICP 
study looking at FXR variants was used, to bring the power up to 80% 119. 
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4. Results 
 
4.1 Study 1: Prospective series 
4.1.1 Subject Details 
 
A total of 152 patients were recruited. All have been referred from outpatient clinics (Imperial 
NHS Hospitals and Rotherham NHS General Hospital) with symptoms of chronic diarrhoea and 
all have had SeHCAT testing with results available.  
 
Table 8 shows the breakdown of patients into the various groups as outlined in the methods 
depending on their diagnosis based on the results of the SeHCAT test; a cut of <15% retention 
at 7 days was used as a positive diagnosis of BAD. A result >15% was regarded as normal 69. 
52.6% (80) of patients were diagnosed with BAD of which 35% had primary BAD.  
 
 
Table 8: Number of patients recruited in each group and % of patients of the total number. 
 
 
4.1.2 BAD groups 
 
The results of the BAD types in relation to the severity of SeHCAT test are presented in  
Table 9.  Out of 80 patients with BAD, Type 1 BAD represented 5% (4 patients) of cases, and 
had severe SeHCAT retention values (≤5%). 68 % of the BAD group were diagnosed with 
primary BAD with the majority having moderate retention values; included in this primary 
BAD group were patients with Type I and II diabetes mellitus.  
 
Chronic Diarrhoea with  
normal SeHCAT 
Bile Acid Diarrhoea Group 
Total Type 1 Type 2 
(primary) 
Type 3 
72 
 
47.4% 
80 
 
52.6% 
4 
 
2.6% 
54 
 
35.6% 
22 
 
14.4% 
68 
Patients presented with Type 3 BAD in 28% of cases. Cholecystectomy, bacterial overgrowth, 
chronic pancreatitis, and Sjogren’s disease amongst others were conditions included in this 
group. 1 patient with Type 3 BAD had more than one pathologic condition associated with 
BAD; they are however only listed once in Table 9, under the condition considered clinically 
the most important. 
 
 
Type of 
BAD 
  SeHCAT results  
  No >10-15% 
Mild 
>5-10% 
Moderate 
≤5% 
Severe 
Total 
BAD 1 Crohn’s disease (TI) 3   3 4 (5%) 
 TI resection 
 
1   1  
BAD 2  
(Diabetics-Type 1&2 
54 
11) 
 
16 23 15 54 (68%) 
BAD 3 Cholecystectomy 
Bacterial overgrowth 
Chronic pancreatitis 
Autoimmune: 
      Sjogren’s disease 
      SLE 
Ileoanal pouch 
Post radiotherapy 
Renal Transplant 
14 
1 
1 
 
1 
1 
1 
1 
2 
 
1 
1 
 
 
1 
8 
 
1 
 
 
 
 
1 
5 
 
 
 
 
1 
1 
 
2 
 
 
22 (28%) 
Total  80 19 
(24%) 
33 
(41%) 
28 
(35%) 
 
80 
 
Table 9: Summary of the patients with associated conditions comprising each BAD group 
according to SeHCAT retention values. 
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4.1.3 Patient Characteristics 
 
Table 10 highlights a number of important patient characteristics between the groups as 
recorded in the patient Chronic Diarrhoea proforma (see appendix 2).  There was no 
significant difference in age and genders between the groups. Median Body Mass Index (BMI) 
was significantly higher in BAD groups compared with chronic diarrhoea groups (24 vs 27, 
p<0.002).   
 
There were an increased number of median bowel movements per day in patients with BAD 
and also in particular patients with primary BAD; a slightly more frequent tendency to open 
bowels nocturnally was seen in BAD groups but not significantly. The duration of diarrhoea 
prior to diagnosis was longer in patients with BAD by 6-12 months but did not reach 
significance when compared with patients with chronic diarrhoea. The stool frequency 
according to Bristol Stool Chart was similar in all groups. 
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 Chronic 
Diarrhoea 
All 
BAD  
Primary  
BAD 
(Type 2) 
Secondary  
BAD  
(Type 
1&3) 
P value 
Age (median value) 
Age range 
45 
17-90 
48 
19-77 
47 
19-73 
55 
26-77 
*p<0.2 
Sex F:M ratio 1.92 : 1 1.4 : 1 1.3 : 1 1.7 : 1  
BMI (median value) 
BMI range 
24 
17-38 
27 
18-45 
27 
18-44 
27 
19-45 
*p<0.002 
Bowel movements 
(median) 
      per day 
 
      per night 
 
 
4.5 
 
0 
 
 
6 
 
0 
 
 
6 
 
0 
 
 
5.5 
 
0 
 
 
*p<0.0014 
**p<0.004 
PBAD vs CD 
 
*p<0.03 
all BAD vs CD 
**p<0.65 
20 BAD vs CD 
Duration of diarrhoea 
(months)(median value) 
18 24 24 30 *p<0.03 
Average stool consistency 
(BSC) 
6 7 6 7  
 
Table 10: Patient characteristics between chronic diarrhoea (CD) and BAD groups. *p values 
are differences between CD and all BAD; **p values are CD vs individual BAD groups as 
above. BSC: Bristol Stool Chart. 
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4.1.4 BMI, Age, Ethnicity, correlations with BAD patients at different SeHCAT 
levels 
 
4.1.4.1 BMI differences in BAD patients at different SeHCAT levels 
 
BMI differences within BAD groups were analysed at different SeHCAT levels to reflect mild, 
moderate, or severe BAD and showed a slightly higher median BMI in the patients with 
primary BAD at a SeHCAT retention value of ≥ 10% than ≥ 15%, but not significantly different. 
There were no other major differences in BMI amongst the groups at lower SeHCAT levels as 
shown in Table 11.  
 
BMI 
 
SeHCAT ≤15% SeHCAT ≤10% SeHCAT ≤5% 
 
 
PBAD (Type 2) 
 
27 
 
28 
 
28 
 
Secondary BAD 
 
27 26 25 
                 Type 1 - - 24 
                 Type 3 28 26 24 
 
Table 11: Median values for BMI in BAD groups at different SeHCAT levels. 
 
 
BMI was negatively correlated with SeHCAT overall and this finding was also noted in the 
chronic diarrhoea group (rs = -0.29, p<0.0001), but poorly correlated in the overall BAD group. 
There was no relationship with BMI and FGF19 in the chronic diarrhoea or overall BAD 
groups; Table 12 and Figure 10a & b. 
 
In primary BAD group there was a significant inverse correlation between BMI and SeHCAT 
retention when the levels were 10% or less; there was an inverse correlation with BMI and 
FGF19 when the overall SeHCAT was 15% or less in the PBAD patients. There were no 
significant correlations in BMI and SeHCAT or FGF19 in the secondary BAD groups (data not 
tabulated).  
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 Overall 
-All patients 
Chronic 
Diarrhoea 
All BAD 
SeHCAT ≤15% SeHCAT≤10% SeHCAT ≤5% 
 rs p rs p rs p rs p rs p 
BMI/SeHCAT 
 
-0.29 <10-4* -0.29 10-3* -0.028 0.40 -0.023 0.43 0.16 0.21 
BMI/FGF19 
 
-0.08 0.16 -0.06 0.30 -0.10 0.19 -0.13 0.15 -0.02 0.45 
 Primary BAD 
SeHCAT ≤15% SeHCAT≤10% SeHCAT ≤5% 
rs p rs p rs p 
   BMI/SeHCAT 
 
 -0.20 0.07 -0.31 0.03* -0.11 0.34 
   BMI/FGF19  -0.28 0.02* -0.20 0.11 -0.04 0.49 
 
Table 12:  Correlation between BMI, SeHCAT at different levels, and FGF19.  CD: chronic 
diarrhoea group; rs = Spearman’s rank correlation; 
*significant p value. 
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Figure 10a: Relationships of BMI to SeHCAT. 
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Figure 10b: Relationships of BMI to FGF19.
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4.1.4.2 Age differences in BAD patients at different SeHCAT levels. 
 
There were no statistical differences in ages between different BAD groups or at different 
SeHCAT levels, even though the median age was slightly lower in all the BAD groups at the 
≥5% SeHCAT levels when compared at 15% SeHCAT level; Table 13.  
 
Age 
 
SeHCAT ≤15% SeHCAT ≤10% SeHCAT ≤5% 
PBAD (Type 2) 
 
47 48 42.5 
Secondary BAD 
 
54.5 54 44.5 
                Type 1 - - 41 
                Type 3 56 55 46.5 
 
Table 13: Median ages in BAD groups and at different SeHCAT levels. 
 
There was a positive correlation with age and FGF19 levels in the chronic diarrhoea group (rs = 
0.27, p<0.01) but not overall.  There was no correlation in age and SeHCAT retention values; 
Table 14 and Figure 11a & b. Age was not significantly associated with C4 or total bile acids 
(data not tabulated), but correlated with BMI in the control group (rs = 0.59, p<0.0001) though 
not in primary BAD. 
 
 Overall 
All patients 
Normal  CD All BAD 
SeHCAT ≤15% SeHCAT≤10% SeHCAT ≤5% 
 rs p rs p rs p rs p rs p 
Age/SeHCAT 
 
-0.04 0.29 0.06 0.29 0.08 0.24 0.09 0.24 -0.05 0.39 
Age/FGF19 
 
0.09 0.13 0.27 0.01
*
 0.025 0.41 0.06 0.32 0.29 0.64 
 Primary BAD 
SeHCAT ≤15% SeHCAT≤10% SeHCAT ≤5% 
rs p rs p rs p 
   Age/SeHCAT 
 
 0.20 0.22 0.06 0.38 -0.14 0.31 
   Age/FGF19  0.09 0.37 -0.12 0.29 0.21 0.22 
 
Table 14: Correlation between Age, SeHCAT at different levels, and FGF19; rs: Spearman’s 
rank correlation; *significant p value. 
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Figure 11a: Relationships of Age to FGF19. 
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Figure 11b: Relationships of Age to SeHCAT.
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4.1.4.3 Ethnicity differences within BAD at different SeHCAT groups 
 
The ratio of ethnic groups between the chronic diarrhoea and BAD groups were similar, 
although there was an increased number of Asians in the secondary BAD groups, which 
reflected in the overall numbers in the total BAD group. This, however, was not significant; 
Table 15.  The ethnic differences in BAD groups were further analysed according to SeHCAT 
levels, to reflect mild, moderate or severe BAD; Table 16. Again no significant differences 
between the groups, although there is some variability in the secondary BAD compared to the 
other groups, but numbers are small. 
 
 
Table 15: Ethnic differences in each group in numbers and percentages of Caucasian (C), 
Asian (A) and Afro-Caribbean (AC).  
 
 
Ethnicity SeHCAT ≤15% SeHCAT ≤10% SeHCAT ≤5% 
C A AC C A AC C A AC 
All BAD 
 
11 
(61%) 
6 
(33%) 
1 
(6%) 
23 
(74%) 
8 
(26%) 
0 
(0%) 
21 
(75%) 
5 
(18%) 
2 
(7%) 
 
PBAD (Type 2) 
 
10 
(66%) 
4 
(27%) 
1 
(7%) 
17 
(77%) 
5 
(23%) 
0 
(0%) 
14 
(93%) 
0 
(0%) 
1 
(7%) 
 
Secondary BAD  
(Type 1&3) 
 
1 
(33%) 
2 
(67%) 
0 
(0%) 
6 
(75%) 
2 
(25%) 
0 
(0%) 
7 
(54%) 
5 
(38%) 
1 
(8%) 
 
 
Table 16: Ethnic differences in BAD groups according to SeHCAT level; numbers and 
percentages of Caucasian (C), Asian (A) and Afro-Caribbean (AC) in each group. 
Groups Total No. 
Patients in 
Group 
Ethnicity (no. in each race) 
C A AC 
Chronic Diarrhoea 
 
72 62 (86%) 8 (11%) 2 (3%) 
All BAD 
 
77 55 (71%) 19 (25%) 3 (4%) 
Primary BAD  
(Type 2) 
 
52 41 (79%) 9 (17%) 2 (4%) 
Secondary BAD 
(Type 1&3) 
24 14 (58%) 9 (38%) 1 (4%) 
77 
4.1.4.4 Other Differences 
 
There were no differences between the BAD and chronic diarrhoea groups with regards to 
smoking, the number of units of alcohol intake per week, the number of coffee cups drunk 
per day, or medications taken by patients.
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4.1.5 Results for Patient associated symptoms 
 
Patient associated symptoms were collected as part of the chronic diarrhoea proforma and 
data was available on 149 patients; these symptoms cumulatively support the diagnosis of 
IBS. The incidence of symptoms is shown in Table 17. Bloating, abdominal pain, and urgency 
were common in patients with BAD but not significantly different from patients with chronic 
diarrhoea. Reported steatorrhoea was seen in approximately 30% of patients with bile acid 
diarrhoea but not significantly different from the chronic diarrhoea group.  
 
There was an increased tendency to report faecal incontinence in overall BAD patients; a 
significant increase was reported in patients with secondary BAD compared with those with 
chronic diarrhoea with faecal incontinence (30% vs 54%, p<0.04).  
 
On further analysis of patients with secondary BAD, there was no significant increase in 
occurrence of faecal incontinence in the Type 1 BAD group (50%), or the Type 3 BAD patients 
who had cholecystectomies (41%) but there was a significant increase in reported occurrence 
in the Type 3 miscellaneous BAD group (6 out of 8, p<0.018), but the numbers were quite 
small.  
 
Table 17: Frequencies of patient associated symptoms occurring in different patient groups. 
CD = chronic diarrhoea group; p value is comparing all BAD vs CD. *p value compares CD vs 
secondary BAD, using Fisher’s exact test.  
 Chronic 
Diarrhoea 
All 
BAD 
Primary 
BAD 
(Type 2) 
Secondary 
BAD 
(Type 1&3) 
New P 
value 
Faecal Incontinence 
 
 
Reported Steatorrhoea 
30% 
 
 
23% 
40% 
 
 
35% 
31% 
 
 
35% 
54% 
 
 
35% 
p<0.17 
p<0.04* 
 
p<0.15 
      
Urgency 83% 92% 92% 92% p<0.13 
      
Abdominal Pain 58% 55% 59% 46% p<0.74 
 
Bloating 
 
 
61% 
 
70% 
 
73% 
 
73% 
 
p<0.30 
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4.1.5 Number of investigations performed for patients 
 
Data was collected on the number of different investigations performed for each individual. 
Data was available for 149 patients. The investigations were performed as part of routine 
testing for patients for chronic diarrhoea and the majority were performed prior to the 
SeHCAT test. Some individuals had more than one type of test, for example an individual 
patient may have had two endoscopy procedures – upper GI endoscopy and a colonoscopy 
performed. The types of investigations performed were discussed in the methods and shown 
in Table 18.  
 
All patients had blood tests and majority had an endoscopy procedure (mainly colonoscopy or 
flexible sigmoidoscopy to exclude microscopic colitis). 27% of BAD patients and fewer of the 
of chronic diarrhoea patients (17 %) had breath tests. 49% of patients had radiology tests and 
more stool tests were performed in the BAD group but in small numbers; Table 18. 
 
 
Groups No. of 
Patients 
Endoscopies Breath 
tests 
Radiology 
tests 
Stool 
tests 
Blood 
tests 
SeHCAT 
test 
Chronic 
Diarrhoea 
72 52 17 28 1 72 72 
 
All BAD  
 
77 
 
54 
 
27 
 
21 
 
7 
 
77 
 
77 
 
Total 
 
149 
 
106 
 
44 
 
49 
 
8 
 
149 
 
149 
 
Table 18: Number of investigations performed for BAD and chronic diarrhoea patients 
including SeHCAT test. Stool tests included microscopy and sensitivity and/or faecal 
elastase.  
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4.1.6 Blood results  
 
Blood results were available in a number of patients (n= 8-50); in particular liver function tests, 
cholesterol and triglycerides, vitamin B12, and vitamin D levels were documented. Table 19 
summarises all the blood results.  
 
There were no statistical differences between any of the blood tests in the BAD groups compared 
with the chronic diarrhoea group. There was a tendency towards higher cholesterol levels in the 
primary BAD group but did not achieve statistical significance. The vitamin D levels were noted to 
be lower in the primary BAD and secondary groups compared with the control group, but again did 
not achieve statistical significance. 
 
 
 
 
Table 19: Blood tests of liver function tests, cholesterol, triglycerides, vitamin B12 and D in 
chronic diarrhoea, primary and secondary BAD;  a p<0.18; b p< 0.12 
  ALT 
(0-40 
IU/L) 
 
Alkphos 
(30-130 
IU/L) 
Bilirubin 
(0-17 
µmol/l) 
Cholesterol 
(<5mmol/l) 
Triglycerides 
(0-2 mmol/l) 
B12 
(160-
800 
ng/l) 
Vitamin D 
(70-150 
nmol/l) 
Control n 
mean 
median 
SD 
 
49 
27 
23 
21 
48 
77 
67 
31 
50 
10 
9 
6 
20 
4.6 
4.5a 
1.2 
20 
1.76 
1.50 
1.20 
41 
406 
383 
194 
23 
55 
51b 
31 
10  BAD N 
mean 
median 
SD 
34 
27 
27 
13 
 
35 
74 
72 
13 
35 
10 
7 
10 
16 
5.1 
5.4a 
1.03 
16 
2.07 
1.64 
1.42 
 
25 
312 
281 
142 
20 
41 
36b 
25 
20  BAD n 
mean 
median 
SD 
 
21 
28 
26 
16 
21 
90 
87 
24 
21 
7 
6 
3.5 
8 
4.3 
4.2 
1.4 
8 
1.68 
1.61 
0.82 
17 
425 
344 
310 
13 
41 
34b 
24 
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4.1.7 Response to treatment 
 
Data was collected on response to treatment with a bile acid sequestrant on the mean number of 
bowel movements pre and post treatment. Table 20 and Figure 12 shows significant (p<0.0035) 
improvements in bowel movements after treatment in primary, secondary and overall BAD groups. 
The mean percentage improvement in bowel movements pre and post treatment was 60.5%. 
There was no difference between percentage improvements between the BAD groups. No 
improvement in bowel movements after treatment was seen in 4 patients.  
 
5 patients were treated with colesevelam, and 17 colestryamine; data from Rotherham Hospital 
was not collected on the type of sequestrant used on the remaining 10 patients.  
 
Bile Acid 
Diarrhoea Type 
  No of Patients Mean BM before 
treatment 
Mean  BM after   
treatment 
        Mean % 
  improvement 
Primary BAD 
(Type 2) 
           22              8            2.3          61% 
Secondary BAD 
                Type 3 
                Type 1 
 
          10 
          N/A 
 
            10 
            N/A 
 
           1.8 
           N/A 
 
         59% 
         N/A 
 
All BAD 
           
           32 
 
             8 
            
           2.1 
           
         60% 
Table 20: Change in bowel movements pre and post treatment in BAD patients; p<0.0035.  
BM = Bowel movements. 
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Figure 12: Bowel Movement response Pre and Post treatment with bile acid sequestrant. 
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The mean number of bowel movements pre and post bile acid sequestrant treatment was also 
observed according to different SeHCAT values, Table 21 and Figure 13. Improvements were again 
significantly noted (p<0.005) in the  groups, and there was a greater tendency for improvement in 
bowel movements after treatment with a SeHCAT value of 5-10% compared to 10-15%. There was 
no difference in the percentage improvement in the ≤5% SeHCAT group compared with the other 
SeHCAT groups. 
 
 
SeHCAT levels No Mean BM before 
treatment 
Mean BM after 
treatment 
Mean % 
improvement 
 
>10-15% 
 
6 7.6 2.1 65% 
>5-10% 
 
15 7.3 1.7 70% 
≤ 5% 
 
11 8.5 2.7 65% 
 
Table 21: Change in bowel movements pre and post treatment in BAD patients according to 
SeHCAT level; p<0.005. BM = Bowel movements. 
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Figure 13: Bowel Movements response Pre and Post treatment according to SeHCAT level 
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4.1.8 FGF19 levels 
 
Fasting serum FGF19 was assayed in all 152 patients recruited. There was a wide variation in 
FGF19 levels. Median fasting levels of FGF19 were significantly lower in patients with BAD 
compared with chronic diarrhoea group with a normal SeHCAT result (median 146 vs. 225 
pg/ml, p <0.001). This data is illustrated in Figure 14.   
 
After differentiating between Primary BAD and Secondary BAD (except Type 3 – see later) 
there were still significant differences in FGF19 levels when compared with the chronic 
diarrhoea group. The statistical significance of the differences in the subject groups is 
summarised in Table 22. 
 
Analysis of variance shows that fasting levels of FGF19 were not statistically different 
between the BAD types (median 102, 146, 192 pg/ml in Type 1, Type 2, and Type 3 
respectively, p <0.13). 
 
Within the BAD group there was a positive correlation between FGF19 and SeHCAT values  
(rs = 0.44, p<0.0001). In primary BAD group FGF19 was lower when SeHCAT was between 0 
and 5% (median 103pg/ml) than when it was 5-10% (133pg/ml) or 10-15% (146pg/ml); Table 
23. This pattern was not however matched in the Type 3 BAD group with FGF19 levels were 
higher at lower SeHCAT values. 
 
The four patients with Type 1 BAD all had very low SeHCAT retention values (<3%) and low 
FGF19 values (<133pg/ml). There was however wide variation and inconsistency in the Type 3 
BAD group. In 14 patients with previous cholecystectomy, although the median SeHCAT was 
6.8%, the median FGF19 was 215pg/ml and did not differ from the chronic diarrhoea controls. 
In the other 8 patients with miscellaneous causes, median SeHCAT was 5.1% and the median 
FGF19 was reduced at 132pg/ml and is significantly different to the controls. 
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Patient Group n FGF19 
(pg/ml) 
P value 
Chronic diarrhoea 72 
 
225  
All BAD 
 
80 146        p<10-5 
Primary BAD 54 
 
146    p<0.0004 
Secondary BAD 
                  Type 1 
                  Type 3 
                  Type 3c 
                  Type 3m 
26 
4 
22 
14 
8 
156 
102 
192 
215 
132 
p<0.005 
p<0.004 
p<0.048 
       p<0.38 
p<0.019 
 
Table 22: Patient numbers and median FGF19 levels in patient groups.  Statistical 
differences between the groups (Mann-Whitney U-test); p values are compared to chronic 
diarrhoea group. Type 3c = cholecystectomy group, Type 3m = miscellaneous group. 
 
 
 
 
Patient Group 
 
n FGF19 (pg/ml) 
SeHCAT ≤15% 
FGF19 (pg/ml) 
SeHCAT ≤10% 
FGF19 (pg/ml) 
SeHCAT ≤5% 
Primary BAD 
(Type 2) 
72 146 133 103 
Secondary BAD 
               Type 1 
               Type 3 
26 
4 
22 
 
0 
192 
 
0 
213 
 
102 
213 
 
Table 23: Median values of FGF19 at different levels of SeHCAT in patients with BAD.  
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Figure 14: Box plot comparing FGF19 levels in Chronic Diarrhoea, Primary BAD and Secondary 
BAD groups. 
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4.1.9 Fasting C4 levels 
 
Fasting C4 levels were measured in 132 patients. C4 levels were significantly higher in patients 
with BAD when compared with patients with chronic diarrhoea (median 22 vs 8 ng/ml, 
p<0.001), Table 24, and Figure 15. This is in keeping with previous studies 114, 77. The overall 
values however in each group are lower than previously reported.  
 
There were no significant differences within the BAD groups (p< 0.04), although C4 levels in 
Type 1 BAD were amongst the highest values, but again numbers were small; this inversely 
mirrors the lower FGF19 levels seen in this group when compared with other BAD groups. 
Within Type 3 BAD group there was no significant differences between the cholecystectomy 
and the miscellaneous subgroups.  
 
There was an inverse correlation between C4 and SeHCAT values within the BAD group 
 (rs = -0.35, p<0.001). In the primary BAD group C4 was higher when SeHCAT was between 0 
and 5% (median 28ng/ml) than when it was at 5-10% (22ng/ml) or 10-15% (18ng/ml). This 
pattern was also seen in the secondary BAD groups; Table 25.  
 
 
Patient Group n C4 
(ng/ml) 
P value 
Chronic diarrhoea 61 
 
8  
All BAD 
 
71 22 p<0.001 
Idiopathic BAD 49 
 
18 p<0.001 
Secondary BAD 
                 Type 1 
                 Type 3 
                 Type 3c 
                 Type 3m 
22 
4 
18 
10 
8 
26  
62 
23 
26 
18 
 
p<0.001 
p<0.001 
p<0.001 
p<0.09 
 
Table 24: Patient numbers and median C4 levels in patient groups.  Statistical differences 
between the groups (Mann-Whitney U-test); p values are compared to chronic diarrhoea 
group. Type 3c = cholecystectomy group, Type 3m = miscellaneous group. 
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Patient Group 
 
n C4(ng/ml) 
SeHCAT ≤15% 
C4(ng/ml) 
SeHCAT ≤10% 
C4(ng/ml) 
SeHCAT ≤5% 
Idiopathic BAD 
 
49 18 22 28 
Secondary BAD 
               Type 1 
               Type 3 
22 
4 
18 
26 
- 
23 
27 
- 
24 
31 
62 
25 
 
Table 25: Median values of C4 at different levels of SeHCAT in patients with BAD.  
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Figure 15: Box plot comparing C4 levels in Chronic Diarrhoea, Primary BAD and Secondary BAD 
groups. 
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4.1.10 Fasting serum total bile acid levels 
 
Fasting serum total bile acids were measured in 136 patients. There was no statistical 
difference in total serum bile acids between patients with BAD when compared with patients 
with chronic diarrhoea (median 2.1 vs 2.1 µmol/l, p<0.99). This is comparable to previous 
studies with similar values 114; Table 26 and Figure 16.  
 
There were no differences in serum total bile acid between BAD groups (p< 0.088). There 
were increased levels in the Type 3 cholecystectomy group, but did not quite reach statistical 
significance. There was a slight increase in total bile acids at a lower SeHCAT values compared 
to higher SeHCAT levels, but again not significant. There was no correlation in total bile acids 
with SeHCAT in the secondary BAD groups; Table 27.  
 
 
Patient Group n Total serum bile acids 
(µmol/l) 
P value 
Chronic diarrhoea 62 
 
2.1  
All BAD 
 
74 2.1 <0.99 
Idiopathic BAD 51 
 
1.7 <0.47 
Secondary BAD 
                 Type 1 
                 Type 3 
                 Type 3c 
                 Type 3m 
23 
4 
19 
11 
8 
2.9  
2.8 
2.9 
3.9 
2.1 
<0.22 
<0.66 
<0.23 
<0.06 
<0.82 
 
Table 26: Patient numbers and median total bile acids levels in patient groups.  Statistical 
differences between the groups (Mann-Whitney U-test); p values are values compared to 
chronic diarrhoea group. Type 3c = cholecystectomy group, Type 3m = miscellaneous group. 
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Patient Group 
 
n Total serum bile 
acids (µmol/l) 
SeHCAT ≤15% 
Total serum bile 
acids (µmol/l) 
SeHCAT ≤10% 
Total serum bile 
acids (µmol/l) 
SeHCAT ≤5% 
Idiopathic BAD 
 
51 1.7 1.7 2 
Secondary BAD 
Type 1 
Type 3 
23 
4 
19 
2.9 
- 
2.9 
3.1 
- 
3.6 
2.9 
2.8 
2.9 
 
Table 27: Median values of total bile acids at different levels of SeHCAT in patients with 
BAD.  
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Figure 16: Box plot comparing total bile acids in Chronic Diarrhoea, Primary BAD and Secondary 
BAD groups. 
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4.1.11 Correlation FGF19 and SeHCAT 
 
The relationship between FGF19 and SeHCAT was correlated and showed a positive 
relationship overall (rs = 0.44 Spearman rank correlation, p< 10
-9), Table 28 and Figure 17. 
Positive and significant relationships of FGF19 and SeHCAT were seen in patients with BAD at 
different levels of SeHCAT. The relationship between FGF19 and SeHCAT was strongest in the 
primary BAD group with an overall SeHCAT value of less than 15% (rs = 0.50 Spearman rank 
correlation, p< 10-5). The relationship of FGF19 and SeHCAT in primary and secondary BAD 
groups was weaker at lower SeHCAT values, Table 29.  
 
 
 All BAD 
FGF19/SeHCAT Overall Normal SeHCAT ≤15% SeHCAT ≤10% SeHCAT ≤5% 
rs 0.44 0.25 0.42 0.39 0.28 
p <10-9* <0.016* <10-5* <0.007* <0.07* 
 
Table 28: Relationships between FGF19 and SeHCAT; rs = Spearman’s rank correlation; 
*significant p value. 
 
 
 
Table 29: Relationship between FGF19 and SeHCAT in BAD Groups at different SeHCAT 
levels; *significant p value. 
 PBAD Secondary BAD (Type 1+3) 
SeHCAT ≤15% SeHCAT ≤10% SeHCAT ≤5% SeHCAT ≤15% SeHCAT ≤10% SeHCAT ≤5% 
rs 0.50 0.41 0.31 0.31 0.41 0.32 
p <10-5* <0.004* <0.12 <0.05* <0.01* <0.13 
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Figure 17: Correlation of FGF19 and SeHCAT. 
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4.1.12 Correlation C4 and FGF19 
 
C4 and FGF19 have a significantly inverse relationship in the primary BAD group (rs = -0.37 
Spearman Rank correlation, p<0.003) and strongest, interestingly when the SeHCAT value was 
≤5% (rs=-0.64, p<0.008); Table 30 Figure 18. This infers that at higher level of C4 which is used 
to diagnose bile acid diarrhoea, there is likely to be an inversely low value for FGF19. The 
relationship did not achieve significance in the control chronic diarrhoea or in the secondary 
BAD groups; Table 31.  
 
 
 
Table 30: Relationships between C4 and FGF19; rs = Spearman’s rank correlation; 
*significant 
p value. 
 
 
 
Table 31: Relationship between C4 and FGF19 in BAD Groups at different SeHCAT levels; 
 rs = Spearman’s rank correlation; 
*significant p value. 
 All BAD 
C4/FGF19 Overall Normal SeHCAT ≤15% SeHCAT ≤10% SeHCAT ≤5% 
rs -0.40 -0.20 -0.35 -0.33 -0.39 
p <10-7* <0.05* <0.001* <0.006* <0.025* 
 PBAD Secondary BAD (Type 1+3) 
SeHCAT ≤15% SeHCAT ≤10% SeHCAT ≤5% SeHCAT ≤15% SeHCAT ≤10% SeHCAT ≤5% 
rs -0.37 -0.34 -0.64 -0.34 -0.41 -0.18 
p <0.003* <0.02* <0.008* <0.05* <0.03* <0.27 
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Figure 18: Correlation of C4 and FGF19. 
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4.1.13 Correlation C4 and SeHCAT 
 
In this correlation C4 was significantly inversely related to SeHCAT in both groups (rs = -0.59 
Spearman Rank correlation, p<10-4), confirming previous work 77; Tables 32 and Figure 19. The 
relationship between C4 and SeHCAT was slightly better in the control diarrhoea group than 
the BAD group. Within the BAD groups the stronger relationship was in the primary BAD 
when the SeHCAT value was ≤10% retention. The relationship at the lower SeHCAT values of 
≤5% however was not significant; Tables 33.  
 
 
 
Table 32: Relationships between C4 and SeHCAT; rs = Spearman’s rank correlation; 
*significant p value. 
 
 
 
Table 33: Relationship between C4 and SeHCAT in BAD Groups at different SeHCAT levels; 
rs = Spearman’s rank correlation; 
*significant p value. 
 
 All BAD 
C4/SeHCAT Overall Normal SeHCAT ≤15% SeHCAT ≤10% SeHCAT ≤5% 
rs -0.59 -0.49 -0.41 -0.41 -0.29 
p <10-4 <10-5 <0.0001 <0.001 <0.07 
 PBAD Secondary BAD (Type 1+3) 
SeHCAT ≤15% SeHCAT ≤10% SeHCAT ≤5% SeHCAT ≤15% SeHCAT ≤10% SeHCAT ≤5% 
rs -0.38 -0.48 -0.16 -0.40 -0.34 -0.54 
p <0.002* <0.001* <0.29 <0.029* <0.07 <0.03 
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Figure 19: Correlation of C4 and SeHCAT. 
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4.1.14 Correlation of Total Bile Acids with FGF19, C4 and SeHCAT 
 
Although there were no significant differences in the total bile acids between the groups, there 
were significant correlations between serum total bile acids and FGF19. This was significant in the 
diarrhoea control group (rs = 0.29, p = 0.01, n = 62), and in fact, was stronger in the group with 
secondary BAD (rs = 0.39, p = 0.03, n = 23). The correlation in primary BAD group (all patients) was 
weaker (rs = 0.21, p = 0.06, n = 51), and again was not significant in those with SeHCAT ≤10% 
(rs = 0.09) or ≤ 5% (rs = 0.06); Table 34a & 34b. 
 
BA were significantly related to C4 in the control group (rs = 0.29, p = 0.01) but not in the other 
groups. The only exception was in the secondary BAD group when the SeHCAT was ≤5% (rs = 0.49, p 
= 0.04); Table 35a & 35b. 
 
BA were inversely related to SeHCAT in those with a SeHCAT <5% (rs = -0.45, p = 0.05), so that 
those with the lowest SeHCAT retention had higher total BA; Table 36a & 36b. 
 
4.1.14.1 BAs v FGF19 correlation at different SeHCAT levels 
 
 
Table 34a: Relationships between BAs and FGF19; rs = Spearman’s rank correlation; 
 *significant p value. 
 
Table 34b: Relationship between BAs and SeHCAT in BAD Groups at different SeHCAT levels; 
rs = Spearman’s rank correlation; 
*significant p value. 
 All BAD 
BA/FGF19 Overall Normal SeHCAT ≤15% SeHCAT ≤10% SeHCAT ≤5% 
rs 0.26 0.29 0.26 0.26 0.19 
p 0.001* 0.01* 0.01* 0.02* 0.16 
 PBAD Secondary BAD (Type 1+3) 
SeHCAT ≤15% SeHCAT ≤10% SeHCAT ≤5% SeHCAT ≤15% SeHCAT ≤10% SeHCAT ≤5% 
rs 0.21 0.08 0.06 0.39 0.42 0.34 
p 0.06 0.30 0.41 0.03* 0.02* 0.12 
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4.1.14.2 BA v C4 correlation at different SeHCAT levels 
 
 
Table 35a: Relationships between BAs and C4; rs = Spearman’s rank correlation;
 *significant p 
value 
 
Table 35b: Relationship between BAs and SeHCAT in BAD Groups at different SeHCAT levels; 
rs = Spearman’s rank correlation; no
 significant p values 
 
4.1.14.3 BA v SeHCAT correlation at different SeHCAT levels 
 
 
Table 36a: Relationships between BAs and SeHCAT; rs = Spearman’s rank correlation;
 no 
significant p value. 
 
Table 36b: Relationship between BAs and SeHCAT in BAD Groups at different SeHCAT levels; 
rs = Spearman’s rank correlation; no
 significant p values 
 All BAD 
BA/C4 Overall Normal SeHCAT ≤15% SeHCAT ≤10% SeHCAT ≤5% 
rs 0.13 0.29 0.06 0.02 0.21 
p 0.05* 0.01* 0.28 0.42 0.14 
 PBAD Secondary BAD (Type 1+3) 
SeHCAT ≤15% SeHCAT ≤10% SeHCAT ≤5% SeHCAT ≤15% SeHCAT ≤10% SeHCAT ≤5% 
rs -0.04 -0.08 -0.08 0.13 0.06 0.49 
p 0.39 0.31 0.38 0.26 0.39 0.04 
 All BAD 
BA/SeHCAT Overall Normal SeHCAT ≤15% SeHCAT ≤10% SeHCAT ≤5% 
rs -0.05 -0.02 -0.19 -0.07 -0.25 
p 0.24 0.43 0.04 0.29 0.09 
 PBAD Secondary BAD (Type 1+3) 
SeHCAT ≤15% SeHCAT ≤10% SeHCAT ≤5% SeHCAT ≤15% SeHCAT ≤10% SeHCAT ≤5% 
rs -0.06 -0.04 -0.45 -0.07 0.27 0.13 
p 0.32 0.39 0.05 0.36 0.11 0.33 
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4.1.15 Sensitivities and specificities for FGF19 based on different SeHCAT values 
 
The optimum sensitivities and specificities, PPV and NPV to evaluate the predictive value for FGF19 
based on different SeHCAT values were analysed with a ROC analysis and are shown in Table 37a 
and Figure 20. For a SeHCAT <15% to diagnose BAD the area under the curve (AUC) was 0.68 (95% 
confidence interval: 0.60 to 0.75, p<0.0001). The AUC to detect SeHCAT values <10% and <5% are 
also shown in Table 37a. From the ROC analysis optimal sensitivity and specificity for FGF19 was 
149pg/ml for SeHCAT <15%; other optimum levels at different SeHCAT levels are also shown in the 
table below. These values are similar to the value of ≤145pg/ml suggested in recent studies 114, 125. 
 
The sensitivity of a FGF19 value of ≤149pg/ml to predict a SeHCAT value of <15% was only 54%, but 
this improved to 57% for <10% and to 64% for <5% (Table 37).  
 
 
 
Table 37: Sensitivities and Specificities, Positive Predictive values (PPV), Negative Predictive 
values (NPV), Area Under Curve (AUC) for FGF19 at different SeHCAT levels in BAD. 
 
 
 
 
SeHCAT 
 
Optimum cut off 
level for FGF19 
Sensitivity Specificity      PPV      NPV     AUC   p value 
≤15%      149pg/ml       54%      84%       79      62     0.68 <0.0001 
≤10%      146pg/ml       57%      82%       69      74    0.71 <0.0001 
<5%    133pg/ml      64%    80%      42      90    0.75 <0.0001 
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Figure 20:  Receiver operating characteristic (ROC) curves for FGF19 to detect SeHCAT at 
<15%, <10% and <5% in BAD patients.  AUC:  0.70 (95% CI 0.59 - 0.78), 0.74 (95% CI 0.63 - 
0.85) and 0.78 (95% CI 0.64 - 0.92) respectively (p < 0.0001 for each comparison).  
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4.2 Study 2: Optimization of sampling 
 
4.2.1: Effect of freeze/thaw and blood collection tubes on FGF19  
 
Up to 3 repeat cycles of defrosting and refreezing of the FGF19 serum did not lead to 
significant alterations in FGF19 concentrations as shown in Table 38. The mean percentage 
change of FGF19 levels after 2 freeze-thaw cycles was an increase of 15%. 
 
Table 38 also shows no significant changes in FGF19 levels between the different types of 
blood collection tubes used to collect the blood from the patient. 
 
 
 
Subject Time from blood sample taken to serum extracted and frozen 
 EDTA tube 
 
 
thawed at 
time of assay 
Serum gel 
separator tube 
 
thawed at time 
of assay 
Plain tube 
 
 
thawed at 
time of assay 
x1  
thaw/freeze 
cycle 
at 2 days 
x2 
thaw/freeze 
cycle 
at 5 days 
Control 1 
FGF19 
 
46 
 
44 
 
47 
 
46 
(0%) 
47 
(2%) 
Control 2 
FGF19 
 
163 
 
181 
 
185 
 
191 
(17%) 
213 
(30%) 
Control 3 
FGF19 
28 
 
31 
 
31 
 
27 
(-3%) 
32 
(14%) 
 
Table 38: Effect of thaw-freeze cycles and collecting blood in different blood specimen bottles on 
FGF19. Fasting FGF19 values in pg/ml. Percentages are changes from time 0. 
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Figure 12: Stability of FGF19 levels after thaw/freeze cycles. 
 
4.2.2: Short and long term stability of FGF19 
 
4.2.2.1 Short term stability 
 
FGF19 levels drawn from 3 healthy subjects and processed 3 and 6 hours after being kept at 
room temperature showed negligible variability in levels from blood processed immediately 
at time 0. Table 39 shows FGF19 levels at different time points and the percentage change 
from time 0. The mean percentage change in FGF19 levels after samples are left for 6 hours 
was 8%. 
 
Subject Time from blood sample taken to serum extracted and frozen 
0 hours 3 hours 6 hours 
Control 1 
FGF19 
 
44 
 
48 
(9%) 
51 
(16%) 
Control 2 
FGF19 
181 
 
 
173 
(-4%) 
197 
(9%) 
Control 3  
FGF19 
31 
 
27 
(-13%) 
31 
(0%) 
 
Table 39: Short term stability of FGF19; values in pg/ml; percentages are changes from time 0. 
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4.2.2.2 Long term stability 
 
FGF19 levels drawn from 4 healthy subjects and processed 6 or 8, 12, 24, and 48 hours after 
being kept at room temperature again shows small variability in levels from blood processed 
immediately at time 0. Table 40 shows FGF19 levels at different time points and the 
percentage change from time 0. The mean percentage change in FGF19 levels after samples 
were left for 24 hours is a decrease of 9%, and at 48 hours by 6%. Figure 22 shows stable 
FGF19 levels over 48 hours. 
 
 
 
Subject Time from blood sample taken to serum extracted and frozen 
0 hours 6 hours 8 hours 12 hours 24hours 48 hours 
Control 1  
FGF19  
 
332  
- 
348 
(5%) 
314 
(-5%) 
302 
(-9%) 
348 
(-5%) 
 
Control 2 
FGF19 
 
84 
 
86 
(2%) 
 
- 
78 
(-7%) 
80 
(-5%) 
81 
(-3.5%) 
 
Control 3  
FGF19 
 
290 270 
(-7%) 
 
- 
274 
(-5.5%) 
242 
(-16.5%) 
272 
(6%) 
Control 4 
FGF19 
112 
 
 
 
116 
(4%) 
108 
(-4%) 
104 
(-7%) 
102 
(9%) 
 
Table 40: Long term stability of FGF19; values in pg/ml; percentages are changes from  
time 0. 
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Figure 22: Short and long term stability of FGF19 over hours and days. 
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4.3 Study 3: Day Series 
 
11 patients with Primary BAD had serum levels of FGF19 measured five times over a six hour 
period. The initial 0900 sample was a fasting sample and subsequent samples were taken after a 
standard breakfast and lunch. The 0900 fasting sample was compared with an original fasting 
FGF19 taken previously when patients had initially presented for their SeHCAT test. SeHCAT values 
were also noted for individuals. The data is illustrated in Table 41 and in Figure 23. 
 
 
Code No SeHCAT 
% 
Original 
FGF19 
(pg/ml) 
Total 
BAs 
(µmol/l) 
0900 Break- 
fast 
10.30 12.00 Lunch 13.30 15.00 
BD06 5.4 290 1.5 508  402 440  907 504 
BD90 9.3 268 1.5 114  150 156  358 737 
BD86 11 142 1.2 572  466 198  356 413 
BD81 4.8 125 2.9 77  77 80  100 116 
BD110 6.8 142 0.9 153  195 273  232 866 
BD93 2 146 5.9 92  108 80  106 255 
BD40 5 172 0.9 143  81 86  87 135 
BD38 8.1 406 1.7 119  130 242  410 524 
BD83 6.7 145 1.1 154  226 105  92 80 
BD25 7.3 146 1.3 752  369 242  486 829 
BD118 4 - 1.7 36  59 234  204 296 
 
Table 41: FGF19 levels during the day; original levels of FGF19 and Bile Acids (BAs) shown. 
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Figure 23: Variation of FGF19 levels in 11 PBAD patients during the day.  
 
 
There are a number of patterns that emerge from the data set. The sets of patterns can be 
subdivided into four groups: 
 
1. Flat response: suppressed levels of FGF19 with minimal variation in FGF19 levels during the 
course of the day. FGF19 Levels were generally less than 145pg/ml. This pattern was seen in 
three patients: BD81, BD40 and BD93. BD93 did, however have a late pm surge in FGF19 
levels. Of note all these patients had low SeHCAT values of 5% and less. See Figure 24a. 
 
2. Diurnal variation: expected postprandial rise and fall of FGF19 was seen in five patients 
following meals. This was seen in three patients with FGF19 values taken on the day 
(BD110, BD38, BD118); this diurnal variation was also seen in a further two patients (BD86 
and BD25) if the 9am fasting FGF19 taken on the day was substituted with the original 
fasting level taken at another time previously when they presented for their SeHCAT test. 
SeHCAT values in this group were between 4 to 8.1%. See Figure 24b. 
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3. FGF19 response to breakfast only: this pattern was seen in one patient (BD83) whom had a 
rise in FGF19 levels after breakfast but subsequently fell with a suppressed response with 
low FGF19 levels even with lunch. The SeHCAT value for this individual was 6.7%. See Figure 
24c. 
 
4. FGF19 response to lunch only: this pattern was seen in two patients (BD06 and BD90). 
BD06 had a very high initial fasting FGF19 level and which was maintained during the 
morning with a small variation and had a very high peak after lunch followed by a fall. BD90 
had low fasting and a subsequent flat FGF19 level in the morning but a significant rise after 
lunch and continued rise at 1500. The SeHCAT values in this group were 5.4% and 9.3%. See 
Figure 24d.   
 
There was also notable variation when comparing 0900 fasting FGF19 level when patients 
presented for the day series and their original fasting FGF19 level taken previously at the time of 
SeHCAT.  
 
Three patients had a mean increase of the FGF19 levels by 418 pg/ml (average 331% rise) 
comparing fasting original FGF19 and fasting FGF19 in the day series. A further 3 patients had a 
mean decrease of FGF19 levels by 157 pg/ml when fasting levels were compared between the two 
time points, whilst 4 patients had minimal change and consistently low FGF19 levels below 155 
pg/ml; see Table 41.  
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 Figure 24a: Flat FGF19 response 
 
 Figure 24b: FGF19 rise after breakfast 
 
 Figure 24c: FGF19 rise after lunch 
 
 Figure 24d: FGF19 rise after break & lunch 
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4.4 Study 4: Effect of bowel preparations for colonoscopy on FGF19 
 
The effect of bowel preparations was studied within chronic diarrhoea and BAD groups. 21 
patients had serum fasting FGF19 measured at the time of colonoscopy after bowel 
preparation and subsequently had another fasting FGF19 level taken at a different time point 
without having had bowel prep. Results are displayed in Table 42and Figure 25 and show a 
decrease in the fasting FGF19 value at colonoscopy compared to a different time point but 
not significantly (median 107 vs 158 pg/ml; p<0.36, Mann-Whitney U-test). 
 
Group FGF19 at 
colonoscopy 
pg/ml 
FGF19 at 
alternative time 
pg/ml 
SeHCAT 
Range 
P value 
     
All Patients 
 
BAD  
 
Chronic 
diarrhoea 
107 
 
95 
 
174 
 
158 
 
100 
 
221 
1.5-59% 
 
1.5-11.6% 
 
18-59% 
p<0.36 
 
p<0.40 
 
p<0.56 
     
Table 42: Effect of bowel preparation used for colonoscopy on FGF19; median fasting FGF19 
values in pg/ml; p values are statistical differences between FGF19 levels at colonoscopy vs 
FGF19 at alternative time.  
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Figure 25: Box plots showing changes in median FGF19 in patients with chronic diarrhoea 
taken at time of colonoscopy (FGF19 C) compared to taken at alternative time (FGF19 O). 
Patient Group No Estimated 
median SB 
length post 
ligament of 
Treitz (cm) 
SBS 1  Without distal ileum or               
            colon in continuity 
12 90 
SBS2   distal ileum and/or    
            colon in continuity 
            (distal ileum included) 
11 
 
(2) 
35 
Healthy controls 14 - 
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4.5 Study 5: FGF19 correlation with C4 values from a group of patients 
with chronic diarrhoea in Edinburgh 
 
FGF19 levels were measured in this group of patients with previous known C4 levels. Group 1 
were patients with chronic diarrhea without diagnosis of BAD and normal fasting C4 values 
(<28 ng/ml) and Group 2 were patients with chronic diarrhea diagnosed as BAD based on 
abnormal C4 (>28 ng/ml). There were no significant differences between the two patient 
groups in age (mean 49.5 in group 1 and 51.5 in group 2) or male to female ratio (females 
66% and 71% respectively). 
 
There was a significant difference in the C4 values between Group 1 and Group 2 (median 
values were 62ng/ml and 9ng/ml respectively, Mann-Whitney U-test, p< 0.0001). The median 
FGF19 values were also significantly different between Group 1 and Group 2 (118pg/ml and 
261pg/ml respectively p<0.0001) 125. Table 43 shows the number of patients within each 
Group and the median fasting C4 and FGF19 values. Figure 26 illustrates the difference of C4 
and FGF19 median values in the Groups. 
 
 
Table 43: Data from patients referred to Edinburgh presenting with chronic diarrhea.  Group 
1 patients: chronic diarrhea patients without diagnosis of BAD and normal fasting C4 values 
(<28 ng/ml). Group 2 patients: chronic diarrhea patients diagnosed with BAD based on 
abnormal C4 (>28 ng/ml). Data not available in 6 patients with BAD; rs = Spearman Rank 
Correlation Coefficient.  
Subject 
Group 
No of patients in 
group 
C4 
(ng/ml) 
FGF19 
(pg/ml) 
Correlation 
      rs p value 
Group 1 
 
119 9 261 -0.16 0.04 
Group2 139 62 118 -0.51 0.0001 
 BAD 1 
BAD 2 
BAD 3 
55 
43 
35 
83 
48 
53 
76 
166 
148 
-0.63 
-0.30 
-0.26 
0.0001 
0.03 
0.07 
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Within Group 2, data was available for 133/139 patients with regards to the associated 
disorders and the Type of BAD. Primary BAD accounted for 31% of all the BAD patients. 
40% of BAD patients had ileal disease or resection as a possible cause (Type 1) and 25% had a 
variety of conditions including post cholecystectomy diarrhea, small bowel bacterial 
overgrowth, and coeliac disease indicating Type 3 BAD. The lowest median levels of FGF19 
were seen in Type 1 BAD, who also had the highest C4 values.  These values differed 
significantly between the three types of BAD groups (Kruskal-Wallis H test, p <0.0001).   
 
 
 
 
 
Figure 26: Fasting C4 and FGF19 levels within each Group. Group 1 patients: chronic 
diarrhea patients without diagnosis of BAD and normal fasting C4 values (<28 ng/ml). Group 
2 patients: chronic diarrhea patients diagnosed with BAD based on abnormal C4 (>28 
ng/ml). 
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There was a highly significant inverse relationship overall between FGF19 and C4 levels (rs = 
-0.64, p < 0.001, Spearman rank correlation); i.e. a higher C4 level is associated with a lower 
FGF19 value (Figure 27).  When the groups were studied separately, this relationship was 
much weaker in group 1 patients, with normal C4, than in group 2, with raised C4 (Table 43). 
The inverse relationships between C4 and FGF19 were significant in Types 1 and 2, but not in 
Type 3 BAD (Table 43).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: Inverse correlation between C4 and FGF19 in Edinburgh cohort of patients. 
Fasting C4 and FGF19 values are shown for individual patients.   
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4.5.1 Specificities and Sensitivities 
 
Specificities and Sensitivities were calculated to define values for FGF19 which would predict 
values of C4 and define BAD.  Using a cut off for FGF19 at ≤145pg/ml to indicate a diagnosis of 
BAD (as suggested in the recent study  114), the sensitivity and specificity were 58% and 79% 
respectively to detect C4 at > 28ng/ml, as used to originally define the groups.  Table 44 also 
shows the figures obtained for the detection of higher values of C4 (35, 48 and 50ng/ml), 
which may improve the sensitivity of FGF19 in the diagnosis of patients with possible Primary 
BAD 80, 83.  The results are also shown for a higher value of FGF19 (200 pg/ml) and at 145pg/ml 
for Primary BAD.  
 
A ROC analysis (Figure 28) analyzing the predictive values of FGF19 for a cut-off value of C4 at 
>60ng/ml shows the area under the curve was 0.80 (95% CI 0.74 - 0.87). 51 patients (20%) out 
of the total of 258 were positive at this value. The sensitivity and specificity were 74% and 
72% respectively for the FGF19 cut-off at 14pg/ml, based on the higher C4 value to diagnose 
BAD, and with a higher sensitivity of 81% at a higher cut-off FGF19 value of 200pg/ml with a 
similar negative predictive value. 
 
 
 FGF19 
(pg/ml) 
C4 value 
(ng/ml) 
Sensitivity Specificity PPV NPV 
All patients       
 ≤ 145 > 28 58% 79% 76% 62% 
 ≤ 145 > 35 62% 77% 71% 70% 
 ≤ 145 > 48 67% 73% 57% 81% 
 ≤ 145 > 60 74% 72% 50% 88% 
 ≤ 200 > 28 71% 67% 72% 66% 
 ≤ 200 > 60 81% 58% 42% 88% 
Type 2 BAD       
 ≤ 145 > 28 40% 79% 49% 78% 
 ≤ 200 > 60 64% 64% 15% 95% 
 
Table 44: Sensitivities and specificities for FGF19 to detect abnormal C4; PPV=positive predictive 
value. NPV=negative predictive value.  
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Figure 28: ROC analysis for FGF19 detection of C4 >60ng/ml. True positive and false positive 
rate data are shown for FGF19 in 258 patients (square symbols).  The line of no 
discrimination is also shown. 
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4.6. Study 6: FGF19 in patients with Short Bowel Syndrome (SBS) 
 
There were no differences in median age, and BMI’s between healthy controls and patients 
with SBS or within subgroups of SBS. There was a larger prevalence of females to males in the 
SBS group; Table 45. 
 
The median fasting level of plasma FGF19 was measured in patients with SBS and was 
significantly lower than in healthy controls (66 vs 168 pg/ml; p < 0.0002, Mann-Whitney U-
test).  Median serum FGF19 levels were similar in the SBS1 (patients with distal ileum or 
colon) and SBS2 (patients with colon in continuity) groups (p <0.5);   Table 46 and Figure 
29a&b.  
 
No significant relationship was found between the level of FGF19 and the length of SB left in 
stream in either SBS1 or SBS2 groups (rs = 0.20; p < 0.18 and rs = 0.03; p <0.36 respectively).  
Analysis of factors such as colon in continuity, diagnosis, ileum in stream, and surgery in the 
last 9 months, produced no significant relationships to FGF19. 
 
 
 
 
 
Table 45: Patient demographics and descriptions of surgery. SBS1 = patients with distal 
ileum or colon; SBS2 = patients with colon in continuity. 
 
 
Groups Age 
(median) 
F:M 
ratio 
BMI 
(median) 
Estimated median SB 
length post ligament of 
Treitz (cm) 
Surgery in last 9 
months (total 
no. of patients) 
Healthy 
Controls 
 
   n/a n/a 
SBS 
      SBS1 
       SBS2 
52 
53 
48 
2:1 
2.6:1 
1.5:1 
22 
23 
23 
 
90 
35 
 
5 
5 
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Groups N Median FGF19 
(pg/ml) 
p value 
Heathy controls 
 
14 168  
SBS 
 
       SBS1 
       SBS2 
23 
 
12 
11 
66 
 
64 
66 
 
<0.0002 
 
 
            <0.5 
 
Table 46: Median FGF19 levels in patients with Short Bowel Syndrome. 
 SBS1 = patients with distal ileum or colon; SBS2 = patients with colon in continuity. 
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Figure 29a: Median FGF19 levels in 
patients with Short bowel syndrome 
compared with healthy controls.  
 
Figure 29b: Median FGF19 levels in 2 
SBS groups; p <0.5. 
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4.7 Study 7: Effect of colestyramine and withdrawal on FGF19  
 
The effects of colestyramine administration for two weeks followed by its withdrawal on 
fasting serum FGF19 was studied in two healthy control subjects. FGF19 levels were 
significantly reduced after one day of colestyramine administration from baseline. There was 
a mean percentage reduction of FGF19 levels was by 65%. Control 2 had almost unrecordable 
levels during periods whilst on the bile acid sequestrant. FGF19 levels were taken up to 3 
weeks after stopping FGF19. Table 47 and Figure 30 shows FGF19 levels over this time course.  
 
FGF19 levels in control 1 increased back to baseline within 1 day of ceasing colestyramine and 
within 2 days for control 2 subject. Levels seem to rebound significantly and increase by 2.88 
times from baseline in control 1 and by 2.35 times in control 2 even at 2 weeks later. The 
levels start to fall after reaching their peak but are still elevated from baseline at 3 weeks post 
stopping the bile acid sequestrant. 
 
During this period of administration and withdrawal of the drug there was no reported 
change in bowel habits by the controls. 
 
Subject 
 
Drug  
naive 
On colestyramine Off colestyramine 
Time in 
days 
 
0 1 2 3 7 10 14 15 16 17 21 28 
Control 1 
FGF19 
 
330 148 170 172 86 - 132 324 808 950 402 572 
Control 2 
FGF19 
 
274 64 2 2 44 80 2 56 438 430 644 438 
 
Table 47: Fasting FGF19 levels at baseline, on colestyramine and after stopping medication 
over the course of 4 weeks. 
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Figure 30:  Line plot: decrease and increase of FGF19 after colestyramine commencement and 
cessation.           = cut off FGF19 level of >140 pg/ml previously used in studies 114 to suggest a 
diagnosis of BAD. 
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4.8 Study 8: Genotyping 
 
There were in total 92 patients with primary bile acid diarrhoea and 75 controls were 
included. The demographics of the patient group and control subjects are summarized in 
Table 48. There was no statistical difference between age, gender and ethnicity. The average 
concentration of extracted DNA was 66.8ng/µl and ranged from 3 to 687ng/µl. These samples 
were all diluted to a standard concentration of 3-25ng/µl. The purity of DNA (A260/280 ratio) 
ranged from 1.7-1.9.  
 
 
Primary BAD 
Patients 
Controls p value 
n  92 75 
 
Age ( Mean ± SEM )  
Range 
46 ± 1 
19-72 
48 ± 2 
17-90 
0.35 
 
Gender  M:F Ratio  31:35 24:53 0.06 
Ethnicity  W:A:AC 
White (W), Asian (A), Afro-
Caribbean (AC)  
50:13:2 59:15:3 0.9 
SeHCAT  % (Mean ± SEM)  6 ± 0.5 22.1 ± 2.2 < 0.001 
 
Table 48: Patient demographics in patient group (PBAD) and control subjects.  
 
 
The allelic discrimination plots of the 6 PCR plates performed are shown in appendix 3. Each 
individual was assigned a genotype, either homozygous wild type (GG or AA), heterozygous 
(GA) or homozygous SNP (GG or AA or TT).  
 
The SNP’s in the FGF19, FXR, Klotho β, and OSTα were identified amongst the different groups 
and no statistically significant differences in the prevalence of the SNP’s between the patient 
and control groups were found. Table 49 to 54 highlights the numbers and types of genotypes 
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in the control, PBAD and cholecystectomy groups with further divisions of ethnicity. Table 55 
summarises the findings. 
 
The -1g>t variant was identified in the heterozygous state (GT) in 5 patients and the 
remaining 61 patients were homozygous for the wild-type allele (GG) in PBAD group. In the 
control group 3 individuals were found to be heterozygous for the SNP and 88 homozygous 
wild-type. 1 individual was identified as homozygous for the SNP (TT) and is the first to be 
identified in this population. Notably however this individual was Caucasian in origin with a 
normal SeHCAT retention test and no other associated diseases. Allele frequencies of the SNP 
were found to be 2.8% and 2.6 % in the Caucasian control and PBAD patients respectively 
(p=0.75, OR 0.65; 95% CI, 0.16- 2.52) (data is shown in Table 51) and were similar to 
frequencies found in previous studies looking at –1g<t polymorphism in the 
Caucasian/European population 118, 119.  
 
To increase the numbers of the control Caucasian group, data was combined from a previous 
case-control study using healthy pregnancy controls looking at this -1g<t polymorphism in 
intrahepatic cholestasis of pregnancy(ICP) cases 118. This study had 290 British controls of 
which 14 were found to be carriers of the SNP. Combined analysis of the two groups in 
comparison with PBAD Caucasians again found no significant difference (p=0.72).  
 
Stratifying for SeHCAT levels did not produce any significant differences between the control 
group and the patient group.  
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SNP FGF19 rs1789170 
 
 Genotype Minor Allele 
Frequency % 
Group 
 
 n GG GA AA  
Control 
 
Total 
C 
A 
AC 
89 
69 
15 
3 
48 
38 
8 
1 
30 
23 
5 
1 
11 
8 
2 
1 
29a 
28b 
30 
50 
PBAD Patients Total 
C 
A 
AC 
73 
57 
14 
2 
30 
22 
6 
2 
36 
29 
7 
0 
7 
6 
1 
0 
34a 
36b 
32 
0 
Cholecystectomy 
patients 
Total 
C 
A 
AC 
18 
14 
3 
1 
8 
7 
0 
1 
6 
5 
1 
0 
4 
2 
2 
0 
39 
32 
83 
0 
Table 49: Prevalence of SNP FGF19 rs1789170 in patient groups; ap<0.35, bp<0.36;  
C: Caucasian, A: Asian, AC: Afrocarribean. 
 
 
SNP FGF19 rs948992 
 
 Genotype Minor Allele 
Frequency % 
Group 
 
 n GG GA AA  
Control 
 
Total 
C 
A 
AC 
92 
72 
16 
3 
11 
6 
3 
2 
37 
27 
8 
0 
44 
39 
5 
1 
31 a 
27 b 
43 
67 
PBAD Patients Total 
C 
A 
AC 
76 
58 
16 
2 
6 
3 
2 
1 
35 
25 
10 
0 
35 
30 
4 
1 
31 a 
27 b 
44 
50 
Cholecystectomy 
patients 
Total 
C 
A 
AC 
25 
16 
7 
1 
3 
1 
1 
1 
8 
4 
4 
0 
13 
11 
2 
0 
28 
19 
42 
100 
Table 50: Prevalence of SNP FGF19 rs948992 in patient groups; ap<0.91, bp<1;  
C: Caucasian, A: Asian, AC: Afrocarribean. 
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SNP FXR -1g>t rs56163822 
 
 Genotype Minor Allele 
Frequency % 
Group 
 
 n GG GT TT  
Control 
 
Total 
C 
A 
AC 
92 
72 
15 
3 
88 
69 
15 
2 
3 
2 
0 
1 
1 
1 
0 
0 
2.7a 
2.8b 
0 
1.6 
PBAD Patients Total 
C 
A 
AC 
66 
50 
14 
2 
61 
47 
12 
2 
5 
3 
2 
0 
0 
0 
0 
0 
3.3a 
2.6b 
6 
0 
Cholecystectomy 
patients 
Total 
C 
A 
AC 
15 
11 
3 
1 
15 
11 
3 
1 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
Table 51: Prevalence of SNP FXR -1g>t rs56163822 in patient groups; ap<0.75, bp<1;  
C: Caucasian, A: Asian, AC: Afrocarribean. 
 
 
SNP M173T rs61755050 
 
 Genotype Minor Allele 
Frequency % 
Group 
 
 n AA AG GG  
Control 
 
Total 
C 
A 
AC 
91 
71 
15 
3 
89 
70 
14 
3 
2 
1 
1 
0 
0 
0 
0 
0 
1.1a 
0.7b 
3.3 
0 
PBAD Patients Total 
C 
A 
AC 
75 
57 
16 
2 
73 
55 
16 
2 
2 
2 
0 
0 
0 
0 
0 
0 
1.3a 
1.7b 
0 
0 
Cholecystectomy 
patients 
Total 
C 
A 
AC 
18 
14 
3 
1 
17 
13 
3 
1 
1 
1 
0 
0 
0 
0 
0 
0 
2.7 
3.6 
0 
0 
Table 52: Prevalence of SNP M173T rs61755050 in patient groups; ap<0.25, bp<0.59;  
C: Caucasian, A: Asian, AC: Afrocarribean. 
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SNP Klotho β rs17618244 
 
 Genotype Minor Allele 
Frequency % 
Group 
 
 n GG GA AA  
Control 
 
Total 
C 
A 
AC 
84 
60 
8 
2 
53 
33 
5 
1 
25 
23 
2 
0 
6 
4 
1 
1 
22a 
26b 
25 
50 
PBAD Patients Total 
C 
A 
AC 
75 
58 
15 
2 
48 
39 
7 
2 
25 
17 
8 
0 
2 
2 
0 
0 
19a 
18b 
27 
0 
Cholecystectomy 
patients 
Total 
C 
A 
AC 
17 
13 
3 
1 
8 
6 
1 
1 
9 
7 
2 
0 
0 
0 
0 
0 
26 
27 
33 
0 
Table 53: Prevalence of SNP Klotho β rs17618244 in patient groups; ap<0.58, bp<0.16;  
C: Caucasian, A: Asian, AC: Afrocarribean. 
 
 
SNP OSTα rs939885 
 
 Genotype Minor Allele 
Frequency % 
Group 
 
 n GG GA AA  
Control 
 
Total 
C 
A 
AC 
89 
64 
14 
4 
30 
21 
3 
0 
39 
27 
9 
2 
20 
16 
2 
2 
44a 
46b 
79 
100 
PBAD Patients Total 
C 
A 
AC 
57 
43 
12 
2 
19 
14 
5 
0 
30 
25 
3 
2 
8 
4 
4 
0 
40a 
38b 
46 
50 
Cholecystectomy 
patients 
Total 
C 
A 
AC 
17 
13 
3 
1 
8 
6 
1 
1 
9 
7 
2 
0 
0 
0 
0 
0 
26 
27 
33 
0 
Table 54: Prevalence of SNP OST α rs939885 in patient groups; ap<0.55, bp<0.53;  
C: Caucasian, A: Asian, AC: Afrocarribean. 
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SNP      rs ID 
Minor Allele Frequency 
Primary BAD group % 
Minor Allele Frequency 
Control group  % 
  All patients 
 
   Caucasian   All patients    Caucasian 
 
FGF19 
 
 
rs948992 
 
          31 
 
           27 
 
            31 
 
         27 
FGF19 
 
rs1789170           34            36             29          28 
FXR -1g>t 
 
rs56163822           3.3            2.6             2.7          2.8 
M173T 
 
rs61755050           1.3            1.7             1.1          0.7 
Klotho β 
 
rs17618244           19            18             22          26 
OSTα 
 
rs939885           40            38             44          46 
 
Table 55: Summary table of SNP’s genotyped and Minor Allele Frequencies in patient groups. 
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5. Discussion  
 
5.1 FGF19 protein and relationships with SeHCAT, C4 and total bile acids 
 
5.1.1 Prospective Series 
 
It has been possible to measure FGF19 levels in a prospective cohort of 152 patients who 
have presented to the outpatient department with symptoms of chronic diarrhoea. These 
patients have been carefully characterised into groups including patients with chronic 
diarrhoea without a diagnosis of BAD (underlying diagnosis is likely diarrhoea predominant 
IBS) and those with either primary or secondary BAD. All patients have undergone a seven day 
SeHCAT test to identify patients with BAD. This is a validated test to diagnose BAD 74,75. 
Fasting serum FGF19 levels have been compared with these SeHCAT findings; a SeHCAT result 
of greater than 15% was regarded as normal 69.  
 
52.6% (80) of patients were diagnosed with BAD of which 35% had Primary BAD. This is in 
keeping with other previous studies 70. Of the patients with PBAD, 43% were diagnosed with 
moderate BAD based on a SeHCAT level of 5-10%, and 28% had severe BAD with a SeHCAT 
level of less than 5%.  This diagnosis of BAD severity based on SeHCAT values was suggested 
by meta-analysis studies of BAD 70. 22 patients were labelled as Type 3 BAD with a number of 
associated conditions with post cholecystectomy patients accounting for a majority.  
 
Fasting FGF19 levels are significantly lower in patients with primary and secondary BAD when 
compared with patients with chronic diarrhoea without BAD. The reduction of FGF19 is most 
notable in patients with the lowest SeHCAT retention, less than 5%, compared with those 
between 10% and 15%.  
 
These results have confirmed similar findings in a small retrospective study measuring FGF19 
in patients with chronic diarrhoea and healthy controls 114. Larger numbers have been 
recruited prospectively in this study; all patients have had SeHCAT tests to confirm BAD, and 
more importantly the results suggest that the reduction of FGF19 in BAD patients is not just a 
consequence of chronic diarrhoea or likely IBS-D.   
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FGF19 and its orthologue FGF15 in mice, has been identified as an enterohepatic signal 
produced by the ileum which is critical to the regulation of bile acid homeostasis 112. The 
proposed model by Walters 101 outlines that low plasma FGF19 would lead to defective 
negative feedback of bile acid biosynthesis and increased bile acid synthesis; this would be 
reflected in the raised C4 levels, which has been shown in other studies 77, 78  and confirmed 
in this study. In this new steady state, ileal transport becomes saturated and increased bile 
acids spill over into the colon, stimulating secretion and causing watery diarrhoea. This 
alternative mechanism may explain an unimpaired bile acid transport found in ileal biopsy 
samples in previous studies 78. The inverse relationship of C4 and SeHCAT retention has also 
been reported by others 78, 80, and again confirmed in this study. 
 
The inverse relationship between fasting FGF19 and C4 as described above was more closely 
related to each other, in patients with an abnormal SeHCAT retention, i.e. BAD patients than 
in diarrhoea controls. The strongest relationship was in the less than 5% SeHCAT retention 
groups in the secondary BA, but also seen in the primary BAD.  
 
This is the first study to show and understand the relationships between the all three 
modalities to test for BAD, and can be related back to the physiology and control of the 
enterohepatic circulation.  
 
5.1.2 Total Bile Acids 
 
There were no significant differences in total serum bile acids between the groups; serum BAs 
may not reflect BA pool, as they are influenced by other factors other than new synthesis, as 
measured by C4, such as ileal BA reabsorption and hepatic uptake 126.  
 
The positive correlation shown between FGF19 and total BAs in the diarrhoea controls, and in 
those with secondary BAD, presumably reflects varying ileal BA absorption and the 
stimulation of FGF19 synthesis that occurs during this process.  It is interesting that this 
positive relationship between FGF19 and total BA is lost in the more severely affected primary 
BAD patients, so that total BAs are inversely correlated with SeHCAT when retention is less 
than 5%.  This supports the proposal that FGF19 synthesis and/or release is impaired in these 
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patients severely affected with primary BAD 114.  BA absorption from the ileum is taking place, 
but insufficient FGF19 is being produced to have a negative feedback role, and consequently 
hepatic bile acid synthesis is excessive.   
 
5.1.3 Retrospective Series 
 
The large cohort of patients from Edinburgh with chronic diarrhoea was a retrospective study 
analysing the relationship between FGF19 and an established blood marker, C4 which is used 
to diagnose BAD 125. The advantages of an FGF19 ELISA test over C4 and also SeHCAT are that 
it would a cheaper and less time consuming test for the patient and the person performing 
the test. 
 
The Edinburgh study showed significant differences in FGF19 and C4 in groups of patients 
with chronic diarrhoea and confirmed findings from the main prospective study and a 
previous study 114. The median serum FGF19 in patients diagnosed with BAD was significantly 
lower than that of patients with chronic diarrhoea per se diagnosed by a previous C4. The 
significant inverse relationship between FGF19 and C4 suggests an important homeostatic 
relationship between bile acid synthesis and its control and in particular suggests that FGF19 
modulates hepatic BA synthesis by suppressing CYP7A1 activity. 
 
Low FGF19 levels are associated with high C4 levels, and conversely, subjects with high FGF19 
values have low C4 values, representing low bile acid synthesis.  This relationship is most 
marked with the best inverse correlation, in those patients with Type 1 BAD, secondary to 
ileal disease, but these relationships are also found with significance in patients with primary 
Type 2 BAD, with no other obvious disease. The relationship in Type 3 secondary BAD was the 
weakest, failing to be significant, and this was similar to findings in the main prospective study 
125. 
 
This inverse pattern of FG19 and C4 accounts for the majority of patients in this cohort.  There 
are however groups of patients that do not fit this pattern.  Both values were found to be low, 
representing false positives for FGF19 (<145pg/ml), in 25 out of 119 patients who had low, 
normal values of C4 below 28ng/ml.  This increased to 53 of 186 patients at a higher C4 cut 
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off level of 60ng/ml.  These patients would not be considered to have BAD on C4 criteria.   
Conversely, both values were high, representing false negatives results for FGF19 
(>145pg/ml), in 19 of the 72 patients with C4 values over 60ng/ml.   
 
A number of proposals are considered to account for this loss in the inverse relationship. 
Chronic liver disease, alcohol intake, and hyperlipidaemia are amongst conditions reported to 
elevate the level of C4 77,127,128 and may have not been fully accounted for in this  cohort of 
patients, especially as this was a retrospective study from Scotland and patients past medical 
histories were not collected.  
 
The timing of blood collection may have influenced the C4 and FGF19 values.  Diurnal 
variation of C4 has been well described129,40,130 with C4 levels showing two peaks during the 
day, and values 2 to 4 x higher than the initial 9am values occurring 3-4 hours later 40.  
Although other groups have identified only one peak of bile acid synthesis130, (this 
discrepancy maybe related to complicated indirect techniques and small numbers) there are 
still differences in levels during the day.  A recent review of 1390 patients from the South East 
of Scotland over a 3 year period confirmed that serum C4 levels were significantly higher at 
1200-1300h (median 25, range 12-49 ng/ml) compared with results at 0900-1000h (median 
17, range 9-35 ng/ml) 122. 
 
In this particular study, patients were required to be fasted for the blood sampling, but in 
practice, this is may not have been the case for patients arriving after midday, or may have 
varied in different hospitals.  FGF19 levels are known to vary throughout the day as seen in 
the day series study and are increased following meals with a time course that differs from 
C46.  
 
There may also have been a loss of serum C4 from the collected sample if left for a period of 
time, which would result in an overall lower than expected C4 concentration.  There was also 
at least one freeze/thaw cycle and again this may have altered C4 concentrations. 
 
Fasting FGF19 has been shown to be reduced in metabolic syndrome 131.  Studies in patients 
undergoing bariatric surgery show that grossly obese individuals have significantly lower 
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fasting serum FGF19 levels when compared with non-obese controls 50.  A number of patients 
in this study with normal, low C4 and low FGF19 levels may well be obese, but data regarding 
height and weight were not recorded for this study.  BMI in the prospective study was shown 
to be significantly higher in patients with Primary BAD and has been shown previously 100. A 
similar correction factor for an increased BMI previously used could be employed and may 
correct some of the anomalies with the FGF19 and C4 relationship.  However, in a recent 
large study, no relationship of fasting FGF19 was found in normal subjects with BMI, plasma 
triglycerides or glucose, and unlike C4, did not vary by gender 132. 
 
A further theory to explain a false positive FGF19 levels with a high C4 could be seen in 
proposed model of Primary BAD with increased bile acid synthesis and normal levels of FGF19 
mRNA transcribed in the terminal ileum, with the problem occurring further along the 
pathway.  For example there may be impaired processing, release or breakdown of the FGF19 
protein along the pathway between the enterocyte and the liver or there may be an impaired 
sensing at the level of the hepatocyte, related to the FGF19 receptor, FGFR4, or the co-
receptor, -Klotho.  This model would be similar to that seen to produce type II diabetes, with 
insulin resistance and impaired receptor function.  Studies have shown that mice lacking 
FGFR4 have an increased bile acid pool size and increased expression of Cyp7a1 33 .  Genetic 
variants in -Klotho and FGFR4 have recently been shown to be associated with colonic 
transit in patients with IBS-D 133 and could be prevalent to some extent in PBAD patients. 
 
 
5.2 Predicting BAD using FGF19 
 
Both the prospective and retrospective studies examined the role of predicting FGF19 to 
diagnose BAD, and a potential tool in the future. When comparing against SeHCAT levels, a 
FGF19 value of greater than 149pg/ml predicts with 84% certainty that the SeHCAT value is 
not below 15%, and 90% certainty that it is not below 5%. A performance index of FGF19 
could be used to adjust for C4, BMI, and age; these factors seemed to have an influence on 
FGF19 as discussed later. This correction may improve predictive values.  
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When analysing for a discriminating FGF19 value against C4 to diagnose BAD in the Edinburgh 
study, a negative predictive value of FGF19 value of greater than 145ng/ml for a C4 value 
greater than 60ng/ml was 88% overall. Patients with FGF19 values above this are unlikely to 
have BAD, and are unlikely to benefit from C4 testing, but those with values below this could 
then be investigated with C4 and/or SeHCAT testing, where available.  However the positive 
predictive values, particularly for primary BAD are poor.    There are a number of 
compounding factors that were not accounted for as mentioned earlier and incorporation 
may improve the predictive values. FGF19 assay however is cheaper and simpler than the 
other tests and so could be utilized as an initial screening test in patients with chronic 
diarrhea.  This may confer an advantage over current test strategies and increase the 
recognition of bile acid diarrhea more widely. 
 
 
5.3 Optimisation work 
 
Work in this study has been carried out to validate FGF19 testing as a diagnostic tool for 
diagnosing BAD. It has been shown that freeze/thaw cycles have very little effect of FGF19 
levels; FGF19 level in blood kept at room temperature prior assay by the ELISA method is very 
stable even after 48hours, which has implications if this test is used in clinical practice. 
 
 
5.4 Patient Characteristics 
 
Obesity is an important modulator, and patients with BAD were shown to have a raised BMI 
compared with the chronic diarrhoea control group. The national average in the UK is 25.4 134. 
Being overweight has been shown to be a significant association in primary BAD where the 
median BMI’s in both men and women were about 15% higher 100, and in this study FGF19 
was inversely related to BMI in primary BAD, such that obesity is associated with a low FGF19. 
SeHCAT and BMI have been shown to be inversely related, and the groups show a significant 
difference in BMI.  
 
The mechanism to account for a raised BMI associated with a lower FGF19 value is uncertain. 
This relationship has been shown in obese patients who undergo Roux-en-Y gastric bypass 135; 
130 
the role of bile salts and the BA pool with its affects on FXR mediated FGF19 production is 
likely to play a key role in this process 51.  The metabolic actions of FGF15 have been 
described earlier; studies have shown that mice lacking FGF15 were unable to maintain blood 
concentrations of glucose and FGF19 treatment restored the loss of glycogen in diabetic 
animals lacking insulin 136 and also increased metabolic rate 49; other studies have shown that 
patients with non-alcoholic fatty liver disease (NAFLD) show an unimpaired 
intestinal FGF19 production 137. Both glucose intolerance and fatty liver are associated with 
obesity and certainly FGF19 has an important regulatory role in this. 
 
A recent study by the Mayo clinic, USA showed that patients with IBS-diarrhoea have a higher 
BMI and synthesise and excrete higher levels of BAs than individuals with IBS-constipation or 
healthy volunteers. They used serum levels of C4 to identify patients with IBS-D who have BA 
diarrhoea 138.  
 
There was a small but significant effect of age on FGF19 in this cohort with diarrhoea. The 
reasons for this are unclear. Multiple calculations were performed when examining BMI and 
age differences in BAD patients at different SeHCAT levels; a Bonferroni Correction would 
likely reduce the number of borderline significant results and this adjustment should be 
performed. Previous series of healthy subjects did not show relationships with age 139.  
Gender had no effects on FGF19, unlike the greater C4 values previously reported in males 139.  
There were no major differences in ethnicity between the groups, with a larger predominance 
of Caucasians, which may be representative of the local population.  
 
BAD has typically been associated with chronic watery type of diarrhea with steatorrhoea 27, 
but this study has shown that patients with this condition also complain of other associated 
gastrointestinal problems, which overall can be seen in patients with IBS-D and this makes 
BAD a condition that can be overlooked and misdiagnosed. Urgency, abdominal pain, bloating 
are common in the groups, with a higher prevalence of faecal incontinence in the secondary 
BAD group.  
 
Almost 53% of patients with chronic diarrhoea in this prospective study were diagnosed with 
BAD, and 60-90% of these patients also had common GI symptoms that are fit the Rome II 
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criteria for diagnosing IBS-D. Chronic diarrhoea patients without BAD also had similar 
frequency of associated GI symptoms. A recent study in Sheffield found that only 6% of 
patients with Rome II diarrhoea IBS-D type symptoms had been investigated for BAD 140; the 
pitfalls of a misdiagnosis of IBS-D can lead to a delay in effective treatment for BAD. The 
Sheffield group also highlighted the relatively long delay in diagnosing BAD based on SeHCAT 
result with a median time of 5 months 140. This current study did not collect data with regards 
to the time frame of diagnosis of BAD, but identified that over 70% of patients undergo an 
endoscopic investigation, all patients have blood tests, and approximately 30% have other 
tests including breath tests and radiological investigations. These are all time consuming 
procedures and SeHCAT testing was performed as a second line investigation as per British 
Society Gastroenterology guidelines in the majority of patients 141. Further information on the 
number of outpatient appointments and length of time to diagnosis would be additionally 
helpful to calculate the health economics of BAD. 
 
The duration of diarrhoeal symptoms prior to diagnosis BAD, between 24-30 months 
highlights further the length to time that the condition goes under diagnosed, with the 
presumption that these patients are seen in the primary care setting with a diagnosis of IBS-D, 
with even less understanding  and awareness of the condition than in secondary care. There 
are no articles which relate to the awareness of BAD in general practice.  
 
A previous hypothesis to explain the mechanism underlying BAD leading to diarrhea has 
focused on rapid transit through the bowel 100, with reduced time for reabsorption in the 
terminal ileum. The number of reported bowel motions per day and the average stool 
consistency in the controls was very similar in patients with BAD, although the FGF19 level in 
this control group was similar to previous finding in healthy controls 114. A rapid transit from 
the diarrhea would therefore not explain a reduction of FGF19 in BAD patients due to the 
impaired absorption. Although the bile acid pool or rapid transit time was not measured in 
this study, a difference in the total BAs might be expected, but this discrepancy was not 
shown in this study. Furthermore the effect of colonoscopy preparation, which clears the 
colon of content by inducing osmotic diarrhoea, was not significant, although FGF19 levels 
were lower in the majority of individuals.  The timing of FGF19 sampling should therefore be 
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avoided after colonoscopy preparation until more experience has been obtained regarding 
normal values in health and in those diagnosed with BAD. 
 
 
5.5 Relationship to blood tests and response to treatments  
 
One may hypothesise that with an increase in BA synthesis seen in patients with BAD, there 
may be an alteration in cholesterol levels or lipid metabolism. Results did not show 
differences in cholesterol or lipid levels amongst the groups. The numbers analysed are small 
and the fasting nature needed for lipid studies could not be accounted for in all the patients. 
Previous studies have suggested there may be a correlation between vitamins A and D and 
FGF19 levels. Low dietary vitamin D may lead to reduced FGF19 expression, or alternatively 
reduced absorption of vitamin D into the enterocyte could also lead to reduced FGF19. Data 
presented here analysing the small numbers of samples where vitamin D was measured did 
not allude to any differences between vitamin D levels amongst the groups. Larger numbers 
may provide statistical significance. 
 
Patients diagnosed with BAD can be effectively treated with a bile acid sequestrant, and this 
can dramatically alter patient’s quality of life. This study showed that there was 
approximately 60% improvement in bowel frequency from an average of 8 bowel motions per 
day to 2 following treatment with a bile acid sequestrant. A SeHCAT retention level provided 
some indication to the improvement in response, with a SeHCAT level of <10% showing a 
better response to treatment than 10-15%, although no difference when the SeHCAT was 
<5%, when perhaps a further improvement would be expected. Pooled data has shown that 
responses to a bile acid binder can be graded with different SeHCAT levels and have shown 
better response rates 70. The response to treatment was not correlated to FGF19 levels, and 
this would be interesting to perform as a prospective study to determine the sensitivities and 
specificities of FGF19 to predict response.  
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5.6 Day series 
 
The FGF19 day series also highlights issues with regards to timing of FGF19 sampling and 
raises further potential mechanisms to explore further, despite there being notable variation 
between patients with PBAD. A previous pilot study  showed variable patterns in fasting and 
meal stimulated FGF19 levels during the day 114. In this current study three patients had a flat 
response with no expected postprandial rise in FGF19 levels during the day. These patients all 
were classed as severe BAD based on SeHCAT values of 5% or less. It is plausible in these 
cases, that BA stimulated FXR mediated FGF19 production would be markedly diminished, 
further strengthening the model of impaired FGF19 negative feedback. Other patients had a 
diurnal variation (similar to findings in healthy individuals 6 ) or a partial postprandial 
stimulation variation to FGF19; although patients were asked to stop their bile acid 
sequestrant one week before, and present fasted, this may not have been adhered to, and 
may account for some of the variation; furthermore the study performed showing the effect 
of colestyramine and its withdrawal on FGF19 levels in healthy individuals,  suggests that 
FGF19 does not return to baseline levels even up to two weeks after ceasing the drug. 
Colestyramine is likely to have longer effects on BA pool size and there may be an over 
compensatory rise in FGF19 after a period of suppression by the bile acid sequestrant even in 
PBAD patients.  
 
This variation in patterns of FGF19 response further adds to the suggestions of alternative 
causes of BAD with FGF19 hormonal deficiency representing the most severe form. 
Alternative explanations have been mentioned and there may be other hormonal influences 
and interactions which may affect FGF19 levels and these will need to be explored. 
Perhaps a larger numbers of controls are needed for day series analysis to clearly define 
‘normal’ FGF19 response to meals and ‘naive’ PBAD individuals with no previous exposure to 
bile acid sequestrant should be recruited. Correlation with FGF19 at different time points such 
as a postprandial sample needs to be explored to possible improve the sensitivity and 
specificity of FGF19 as a tool to assess and diagnosis BAD.  
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5.7 FGF19 in Short Bowel Syndrome patients 
 
FGF19 levels were significantly lower in this cohort of patients whom have had small bowel 
surgery compared with healthy controls. These patients are unable to effectively absorb BAs 
in their small intestine which results in impaired FGF19 production from the remaining 
intestine and this is predicted to reduce feedback inhibition of synthesis of bile acids, which 
would overwhelm the absorptive capacity of a short ileum increasing diarrhea. This study 
further adds support to the impairment of negative feedback inhibition of bile acid synthesis 
controlled by FGF19. 
 
 
5.8 Genotyping 
 
The molecular genetics work performed is the first study of polymorphisms involved in bile 
acid metabolism, and FGF19 action in patients with PBAD. The SNPs examined in FXR, FGF19, 
Klotho β, and OSTα gene, were not any commoner in the patient group than the controls.  
Major differences in the frequency of genetic polymorphisms in the candidate genes 
examined are unlikely to be associated with Primary BAD. However, the SNPs identified may 
contribute small effects, with a combination of SNPs in several genes producing a cumulative 
effect.  
 
Polymorphisms in FGFR4 and Klotho have recently been described in a large series of patients 
with IBS-D, and are associated with colonic transit times 133. The function of β-Klotho has 
been shown to be affected by this variation, so FGF19 actions regulating BA synthesis are 
likely to be modulated by such differences.  Consequently, the interpretation of differing 
values of serum FGF19 will depend on knowledge of additional factors including these down-
stream genetic variants.  As discussed some subjects who have low SeHCAT but normal FGF19 
values are likely to have impaired FGF19 signalling. 
 
The first SNP processed was in the FXR gene. The hypothesis was that this was the most likely 
candidate gene to confer associations with the affected condition. This is because bile acid- 
activated FXR controls expression of several genes important in the maintenance of bile acid 
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homeostasis.  In the intestine, these include activation of transcription of FGF19 gene in 
addition to IBABP, OST α/β and short heterodimer partner (SHP), which in turn down-
regulates ASBT expression 6. FGF15 the mouse orthologue, was found to be the most 
responsive gene to FXR when treated with the FXR agonist GW4064 13. In theory, variation in 
the FXR gene could potentially disrupt this regulation of expression of FGF19 and other 
enterocyte-expressed target genes. This could result either through the formation of a 
truncated protein or through reduced transcription or translation efficiency (as could be the 
case with -1g>t polymorphism due to it being a non-coding variant). 
 
Of a trivial interest there was a detection of a rare homozygous individual for the SNP in the 
FXR -1g>t, which is the first to be identified in the population. This individual however was a 
control, of Caucasian origin with a normal SeHCAT value and no other significant diseases. 
 
Functional analysis of the G-1T variant in recent studies, have found that it is associated with 
reduced activity, through decreased translational efficiency leading to reduced levels of FXR 
protein 12. This in turn could result in reduced expression of FGF19 resulting in a phenotype 
resembling PBAD. 
 
Although this study has sufficient power to detect a 4-fold increase in frequency of a SNP in 
PBAD patients, it cannot exclude the possibility of a weaker association which would need a 
larger sample size to be detected. Therefore although it appears unlikely that there is an 
association with the SNPs studied and PBAD, this needs further sampling before this 
statement is fully contradicted. It is possible that polymorphisms in the genes involved with 
BA metabolism have a modifier role in the aetiology of PBAD in conjunction with other loci.  
 
If an association were to be found in the future, this study shows that the gene variants are 
not fully penetrant, as some control subjects also possessed the variants without developing 
PBAD therefore interaction with other factors and genes may also be involved.  
 
It is understood that SNPs confer a minor effect on disease susceptibility, and so it is possible 
that as with other complex diseases, this SNP contributes a small effect to a combination of 
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other SNPs in several genes producing a cumulative effect and conferring susceptibility to 
PBAD (it is unlikely to be a simple Mendelian inheritance).  
 
There is also the possibility that PBAD may be caused by the interaction of genes and 
environmental factors as seen in a number of other complex gastrointestinal diseases. Thus 
even if individuals have polymorphisms in certain genes predisposing them to the condition, 
an environmental trigger may be necessary for the disease to develop. This is suggested by 
the finding that some patients report an episode of acute gastroenteritis before the onset of 
PBAD, implying that an infectious trigger may be present 110.  
 
It seems clear from this study that the polymorphisms in the candidate genes studied are 
unlikely to be associated with PBAD. However, further studies involving a larger cohort of 
subjects are required. Future studies could also look at a number of other candidate genes 
involved in the FGF19-FGR4 axis. 
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6. Summary 
 
In summary, this body of research has prospectively confirmed that levels of an easily 
measurable and reliably stable hormone, FGF19, which is critically involved in bile acid 
metabolism is reduced in patients with BAD and is not affected by chronic diarrhoea per se; 
this provides evidence that a disordered FGF19 production by the ileum can be found in 
patients with primary BAD, which in turn fails to reduce bile acid secretion by negative 
feedback which ultimately results in excess bile acids entering the colon causing bile acid 
diarrhoea. 
 
More severely affected patients with lower SeHCAT retention have a greater deficit. There is 
an association with age and BMI suggesting other metabolic factors at play. Patients with BAD 
have a number of commonly associated GI symptoms and this can make it difficult clinically to 
separate it from diarrhoea predominant IBS.  
 
There is an appropriate inverse association of FGF19 with bile acid synthesis and positive 
correlation with known available tests that are currently being used to diagnose the 
condition. 
 
Other hypotheses relating to defective FGF19 function or interaction further in the 
enterohepatic circulation have been proposed as a consequence of findings from the 
retrospective series and the day series of FGF19 levels in patients with BAD.  
 
Although the pathophysiology for this relatively common gastroenterological condition has 
been now been established, the cause for the impaired FGF19 production and/or action is not 
apparent and needs further investigation and may be related to a combination of genetic and 
environmental influences.
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7. Future Work 
 
Further recruitment of patients with Primary BAD will further the understanding of the 
condition and in particular the role of FGF19 as a potential tool in the diagnosis of the 
condition. Unanswered questions to the role of genetic defects leading to impaired FGF19 
synthesis and/or signalling (FGFR4/Klotho β) require greater patient numbers and 
exploration.  
 
Future genetic studies should focus on the candidate gene approach, with further recognition 
of the condition and identification of more patients with PBAD, there is a possibility that 
linkage studies and genome wide-association studies may have a greater effect and potential. 
Recent genome wide association studies of common gastrointestinal diseases have 
considerably enhanced our understanding of the pathogenesis of these conditions.  
 
Recruitment is continuing to enlarge the pool of PBAD patients for the day series to further 
analyse patterns and look for prevalence of additional polymorphisms in other parts of the BA 
metabolism pathway. A recent study in patients with IBS-D found that a SNP in FGFR4 was 
associated with the stool levels of BAs, which was found to be higher in patients with IBS-D, in 
addition to a higher level of C4 138.  
 
The sensitivity and specificity of FGF19 was calculated in this prospective study and compared 
with C4 measurements in the Edinburgh cohorts. By exploring this in further detail, by 
accounting for variables, refining the timing of FGF19 sampling,  and analysing the response 
to sequestrants, it may be possible to define a fasting level of FGF19 that will discriminate 
between patients with and without BAD, and could be used as a first line blood test in 
patients presenting with chronic diarrhea. SeHCAT testing, which integrates bile acid loss over 
a seven day period, does not have these drawbacks of sample timing and processing but 
clearly involves more time commitment from the patient to have two scans.   
 
Vitamin A and D in murine models have been found to be essential for the basal synthesis of 
FGF15 39 and abnormalities in the absorption or processing of these vitamins may be 
responsible for reduced levels of FGF19 in PBAD. Levels of these vitamins will need to be 
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measured in the prospective cohort collected and in addition further samples to look for this 
association. 
 
A common cause for secondary BAD is Crohn’s disease with previous ileal resection and also 
in patients with non-resected Crohn’s disease. Reductions in BA pool size have been shown to 
relate to disease activity 142. Fasting serum levels of FGF19 are reduced in patients with 
Crohn’s disease involving the ileum and also in patients with Crohn’s disease and ileal 
resections. Further work to explore the relationship with FGF19 levels to assess Crohn’s 
disease activity is currently being undertaken.  
 
 
7.1 Ileal FGF19 transcripts 
 
Previous studies have demonstrated FGF19 transcripts in ileum and found large variation in 
levels when compared with other transcripts. There was also a suggestion that overall levels 
may be higher in the patients with diarrhoea 143.  In these studies SeHCAT testing was not 
performed on all patients that had ileal FGF19 transcripts studied and therefore the studies 
will need repeating with specific controls and new samples.  
 
Ileal biopsies from patients with BAD and healthy controls have been collected in RNAlater, 
and stored for RNA preparation.  Further studies will need to determine the expression of 
transcripts for FXR, the basolateral transporters OST and OST, IBABP and ASBT.  This will 
enable a more comprehensive picture of the interrelationships of transcripts in PBAD, and 
clarify the distribution of FGF19 expression and the induction of human ileal FGF19 by BAs. 
 
 
7.2 Therapeutic roles  
 
The discovery of FGF19 in the pathogenesis of primary BA diarrhoea has lead to considering 
possible novel therapeutic options. There may be a therapeutic role in PBAD in taking 
exogenous vitamins A and D, if differences are found in patients with this condition. 
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Reduced FGF19 levels have been found in patients with PBAD, and the model of deficient 
FGF19 expression by FXR in response to BA has been discussed. It would be intuitive therefore 
to look at FXR agonists to stimulate FGF19 production to reinstate to levels to allow negative 
feedback inhibition of BA synthesis. The use of FXR ligands has recently been shown to offer 
potentially important therapeutic benefits in patients with primary biliary cirrhosis. 6α-ethyl-
chenodeoxycholic acid (6-ECDCA) and GW4064 have been found to be potent synthetic 
agonists of FXR and may therefore have a potential therapeutic role in this condition in the 
future 144. The use of FXR agonists such as obeticholic acid and its affect on FGF19 is being 
evaluated. 
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9. Appendix 1 
 
9.1 Patient quotes 
 
Various quotes collected from patients suffering from bile acid diarrhoea during period of 
research.  
 
 “unpredictable, embarrassing, miserable, limits activities” 
 
“worried or scared about going out for a meal” 
 
“I stay home a lot of the time” 
 
“as a teenager and in my 20’s its ruined many a date” 
 
“I have to know where the toilets are” “I have to plan my car journeys” 
 
“missed university lectures, taken days off work, stops me coming to work” 
 
“stopped work as a makeup artist” 
 
“could not travel on public transport” 
 
“had many parking tickets (travelling salesman rushing into public toilets)”  
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9.2 Chronic Diarrhoea Proforma 
 
 
   
    
 
  
   
PATIENTS WITH CHRONIC DIARRHOEA      
Participant no:  
  
Hospital site:  HH CX St Marys 
Date:             RGH     
Patient Details               
          Age: 
 
Sex: M / F 
  
   
  
   
  
        ADDRESSOGRAPH LABEL 
 
  Ethnicity: White Asian-Indian Mixed 
  
   
    
Afro-
Caribbean 
Asian-SE Other 
  
   
  
   
  
  
   
  Phone: Home: Mobile:   
Height:      Weight:    
 
BMI:      
Chronic Diarrhoea Characteristics 
(give all 
details)           
No. of bowel 
movements:   
/ day  
 
/ night 
 
>25% of time:   Y  /  N 
Duration of symptoms:  
      
  
Stool consistency:  
(see Bristol Stool chart on 
reverse)     
Abdo pain:  Y  /  N 
** Blood in stool:  Y  /  N 
    
Bloating:   Y  /  N 
** Unintentional Weight 
Loss: 
Y  /  N  Amount : 
   
Incontinence: Y  /  N 
Steatorrhoea:   Y  /  N 
     
  
Any known dietary factors: e.g. wheat or milk intolerance  
    
  
Family History  (give details if positive)           
 
Colorectal Neoplasia 
 
 
IBD 
  
Coeliac disease 
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9.2 Chronic Diarrhoea Proforma 
 
Past Medical 
History  
(give date & details)           
IBD 
 
Thyroid DM 
 
Pancreatic  
 
Other significant PMHx 
Previous Surgery  (give date & details)           
Ileal 
resection   
Cholecystectomy 
 
Gastric surgery 
 
Other GI   
Drug & Social 
History 
              
Drugs: 
 
(Note Mg products, NSAIDs, antibiotics, metformin, anti-hypertensives/-arrhythmics/-neoplastic 
drugs) 
ETOH:  
 
units / week 
  
Smoking: 
 
/day & no.of years 
Recent foreign travel:  Y  /  N   
  
Coffee intake:  
 
/day   
Examination (Positive Findings)             
  
       
  
Investigations    
(√  if normal results obtained 
or R if requesting)             
Blood tests: FBC   Iron studies   Na   Bili   
  CRP   B12   K   Alkphos   
  TFT   Folate   Ca   ALT   
  Coeliac serology      Glucose   GGT   
  Research blood?           Research Consent signed? Y  /  N   
Stool tests: OC&P 
 
Faecal elastase:  
   
  
SeHCAT test:            
 
% 
    
  
Colonoscopy: TI Bx:  Histology:  Y  /  N   
 
Research Bx:   Y  /  N     
  
 
Colonic Bx:   
 
Y  /  N 
   
  
Other 
tests: 
Lactose Hydrogen Breath Test (for lactose malabsorption): 
 
Other: 
 
  
(as 
indicated) 
Glucose Hydrogen Breath Test (SIBO):  
    
  
  Imaging:   U/S 
   
CT abdomen 
 
  
Group 1. Primary Bile Acid Diarrhoea   3. Idiopathic diarrhoea   
5. 
Control 
  2. Secondary Bile Acid Diarrhoea   4. Other (give details)      
       
SP / JW 11/2008 
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9.3.1 Allelic discrimination plot of PCR plate for SNP rs1789170 
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9.3.2 Allelic discrimination plot of PCR plate for SNP rs948992 
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9.3.3 Allelic discrimination plot of PCR plate for SNP rs56163822 
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9.3.4 Allelic discrimination plot of PCR plate for SNP rs61755050 
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9.3.5 Allelic discrimination plot of PCR plate for SNP rs17618244 
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9.3.6 Allelic discrimination plot of PCR plate for SNP rs939885 
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